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Propofol (PRO), an intravenous (i. v.) hypnotic, has rapid onset and short duration of 
action used for both induction and maintenance of general anesthesia by a continuous infusion 
during surgical procedures. Total intravenous anesthesia (TIV A) is a technique of general 
anesthesia using a combination of i. v. administrated drugs without the traditional inhalational 
or balanced anesthetics. Owing to its desirable pharmacologic properties, PRO is usually used 
in TIV A. PRO has many properties such as antiemetic, anticonvulsant and antioxidant 
activities; but it has no analgesic properties. Therefore, a narcotic synthetic opioid (form 
fentanyl-family) is usually administered concomitantly with PRO in TIV A. 
Remifentanil (REM) is an ultra-short-acting opioid appears to be an ideal analgesic 
(than other fentanyl-family members) used for TIV A in a combination with PRO. REM has 
unique properties that are different than its congeners and similar to PRO such as a rapid 
onset and short duration of action; as well as the independent pathway from PRO as REM's 
clearance is caused by non-specific blood and tissue esterases. 
The use of PRO and REM in a combination during anesthesia results in a reduction in 
doses requirement of both agents because they interact pharmacodynamically and act 
synergistically in the response of hypnosis and nociception. The TIV A with PRO and REM is 
a very accurate, easy, and predictable, environmentally safe and without the most common 
side effect after inhalational or balanced anesthesia, postoperative nausea, and vomiting 
technique. Unfortunately, the overdosing of PRO or REM during TIV A causes cardiovascular 
depression and may be death in many reported cases. Accordantly, the monitoring of PRO 
and REM plasma concentrations at the stable maintenance phase of anesthesia is required. 
Moreover, the pharmacokinetic (PK) interaction studies would clearly add to the knowledge 
base of specialists in the field of anesthesiology, specially the effect of REM on plasma 
concentration of PRO has not confirmed yet. 
The published analytical methods for determination of PRO or REM in the different 
biological samples have been developed independently, therefore a simultaneous method for 
their determination is required for easily and rapid PK drug-drug interaction analysis. 
On the second research point in this thesis we study the effect of drugs, used in 
treatment of epileptic patient, on PRO plasma concentration during anesthesia; as the epilepsy 
is much relevant to the anesthesia for the reasons of the interactions between the anti epileptic 
drugs (AEDs) and co-administrated ones, commonly postoperative seizures, and the intensive 
care management of status epilepticus. 
Carbamazepine (CBZ) is an AED and the standard treatments for epilepsy since 
1970s and still is. Unfortunately, CBZ plasma concentration is closely related to its curative 
effect and toxic side effects. Therefore, it is necessary to monitor its plasma concentration to 
improve the curative effect and decrease toxic side effects. Also, benzodiazepines such as 
midazolam (MDZ) are used in clinical practice mainly for the induction of anesthesia or as an 
anticonvulsant in patients with generalized seizures or status epilepticus. Patients with 
epilepsy often require anesthesia for elective and emergency surgery. For these patients, an 
appropriate perioperative management of administrated AEDs is vital in maintaining seizure 
control. 
From the literatures, PRO is mainly oxidized by hepatic enzymes cytochrome P450 
(CYP) 2B6 and CYP2C9. Inversely, it inhibits the activities of CYP2Al, CYP2C9, CYP2D6, 
and CYP3A4 enzymes. Since CYP3A4 is responsible for CBZ metabolism, co-administration 
of PRO and CBZ is expected to have a drug interaction. On the other hand, CBZ induces 
CYP1A2, CYP2C9, and CYP3A4 activities; therefore PRO that undergoes metabolism via 
CYP2C9 is likely to be affected. Also from the literatures, MDZ is neither inhibitor nor 
inducer for CYP3A4 metabolism, however it has been proposed for the hepatic CYP3A 
phenotyping (assessing the functional CYP3A activity). 
The influence of MDZ on PK of PRO and other anesthetics has been described in 
details in the reported literatures. To date, there are no data that describe whether, and to what 
degree, CBZ affects the plasma concentration of PRO and also the published analytical 
methods for determination of PRO, MDZ, or CBZ in biological samples have been developed 
independently. 
According to the mentioned above, the aim of the present thesis's study to developed 
chromatographic methods used for simultaneous determination of PRO and drugs usually 
used in TIV A such REM and MDZ or drugs relate to patient with epilepsy and has a surgery 
with general anesthesia. The developed and validated methods should be sensitive and 
selective enough to couple with the PK drug-drug interaction analysis for the co-
admin istrated drugs: 
~h~mt~.r..J.:. We described a developed and validated high-performance liquid 
chromatography-ultraviolet detection (HPLC-UV) method for simultaneous determination of 
PRO and REM using fluoxetine as an internal standard (IS). A liquid-liquid extraction (LLE) 
procedure in a basic pH with hexane proved a successful, accurate, and precise extraction of 
the analytes from the pre-treated plasma samples. The linear calibration curves over the 
concentration ranges of 25-2500 ng/mL for both PRO and REM showed high correlation 
coefficients (r) 2: 0.983. The limit of detections (LODs) was 3 and 10 ng/mL and the limit of 
quantifications (LOQs) was 6 and 20 ng/mL for PRO and REM, respectively. Acceptable 
results for the accuracy, intra-day and inter-day precision were obtained. Unfortunately, even 
the developed HPLC-UV was sensitive for PRO determination in plasma, but was not 
sensitive enough for REM to follow its PK study after co-administration with PRO. 
~J!~rntt}r. .. ~: . A selective liquid chromatography-tandem mass spectrometry (LC-
MS/MS), using CBZ as an IS, for simultaneous determination of PRO and REM in rat plasma 
was developed and validated. A LLE procedure in a basic pH with tert-butyl methyl ether was 
used for plasma pretreatment further analysis using electrospray ionization negative or 
positive (ESI· or ESi+) modes for PRO or REM and IS, respectively. 
The linear calibration curves over the concentration ranges of 0.27-10 µg/mL or 0.17-
50 ng/mL for PRO and REM showed high r (2:: 0.981 ). The lower LOQs were 0.27 µg/mL and 
0.17 ng/mL for PRO and REM, respectively. Acceptable results for the recovery from plasma 
samples, accuracy, intra-day and inter-day precision and matrix effect (ME) optimization 
were obtained. The validated LC-MS/MS method has been successfully applied to study on 
the PK interactions of co-administrated PRO and REM to male Wistar rats. 
~h~rn~.t}r..}; A sensitive and rapid HPLC-MS/MS spectrometry for simultaneous 
determine PRO, MDZ and CBZ in rat plasma was developed and validated. A simple and 
rapid solid-phase extraction procedure was used for plasma pretreatment further analysis 
using ESI· or ESi+ modes for PRO or MDZ and CBZ respectively. The linear calibration 
curves over the concentration ranges of 1-100 (using CBZ as an IS), 1-100 (using MDZ as an 
IS) for PRO (two calibration curves for PRO); 2-100, and 7-1000 ng/mL for MDZ and CBZ, 
respectively showed a high r (2:: 0.991). The LOQs were 0.05, 2, and 7 ng/mL for PRO, MDZ, 
and CBZ. Acceptable results for the recoveries from plasma samples, accuracy, intra-day and 
inter-day precision were obtained. The proposed method was successfully applied to study on 
the PK interactions of co-administrated PRO and MDZ or PRO and CBZ to rats. 
!THE CHEMICAL STRUCTURE OF THE INVESTIGATED ANAL YTES-




Fluoxetine, FLU, IS 
Figure 1. Chemical structure of propofol (PRO, MW=l 78.3 g/mol) and remifentanil (REM, 
MW=376.5 g/mol), midazolam (MDZ, MW= 325.8 g/mol), carbamazepine (CBZ, MW=236.3 g/mol) 
and fluoxetine (FLU, MW=345.8 g/mol). 
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I. GENERAL ANESTHESIA 
Anesthesia refers to a condition of reduced sensibility in the body. The term 
comes from the Greek word aesthesia, which means "ability to sense." The prefix a- (an-, in 
the presence of a vowel) is used for negation. Therefore anesthesia stands for "inability to 
sense" and it indicates a "condition of deprived sensibility." Anesthesia is a reversible 
pharmacological state induced by the administration of anesthetic drugs. Delivery of adequate 
anesthesia during medical treatments ensures the patient hypnosis, analgesia and muscle 
relaxation 'l. The types of anesthesia are broadly classified into local anesthesia, regional 
anesthesia (epidural and spinal) and general anesthesia. In modern clinical practice, general 
anesthesia is provided only when strictly necessary in order to reduce the invasiveness of the 
procedure. The goal in the administration of general anesthesia is to provide a stage of 
reversible unconsciousness with adequate analgesia and muscle relaxation for surgical 
procedures. 
Nowadays i. v. anesthetics are largely used for induction and maintenance of general 
anesthesia. Fortunately, an attractive way, which may obviate the need for inhalation of a 
volatile liquid, is the development of the potent ultra-short-acting i. v. agents suitable for both 
induction and maintenance of anesthesia. In this case the anesthesia technique is called total 
intravenous anesthesia (TIV A), therefore, the TIV A can be defined as a technique of general 
anesthesia using a combination of agents given solely by the i. v. route and in the absence of 
all inhalational agents. The technique of TIV A has become popular and practical as it is 
simple, economic, environmentally safe, and associated with less postoperative nausea and 
vomiting than inhalational or balanced anesthesia. 
16 
Consequentially, the introduction of TIV A into the clinical procedures of anesthesia, 
made possible the application of a target controlled infusion (TCI) modem computer 
technology system through which the anesthesiologist attempts to achieve a real-time target 
level of drug in the plasma or effect site, according to the drug's PK. Related to the 
mechanism of action, anesthetic agents have many effects on the lipids and proteins that are 
found in neuronal membranes. In addition, the pore-forming membrane bound proteins (ion 
channels) that help to establish and control the small voltage gradient that exists across the 
plasma membrane of all living cells. The ion channels are divided into families depending on 
amino acid structure and function 2l: 
a) Ion selective gating: as ligand-gated acetylcholine receptor, y-aminobutyric acid 
receptor (GABAA) and glutamate receptors. 
b) Phosphorylation gated: as adenosine triphosphate (ATP). 
c) Voltage-gated: as Na+, K+, and Ca2+. 
There are four main classes of membrane proteins 3l: 
a) Enzymes, such as acetyl cholinesterase, 
b) Transporters for specific molecules, 
c) Neurotransmitter receptors and 
d) Structural proteins. 
The neurotransmitters are endogenous chemicals that transmit signals across a 
synapse (a structure that permits a neuron (nerve cell) to pass an electrical or chemical signal 
to another neural cell). The major inhibitory neurotransmitter in the vertebrate central nervous 
system (CNS) is y-aminobutyric acid (GABA), whose action is produced by its selective 
interaction with at least two classes of receptors, namely GABAA and GABAs receptors 4• 5l. 
Number of distinct classes of drugs such as anesthetics (PRO, benzodiazepines, 
benzodiazepine-like compounds and barbiturate) exert their effects by interacting with 
specific modulatory sites on GABAA receptors 3• 4• 6l. 
17 
Propofol (Propofol®, Diprivan®) 
PRO (2,6-diisopropylphenol, Figure I) 7l is a short acting i. v. hypnotic has the 
advantages of rapid onset and short duration of action due to its rapid hepatic elimination. 
PRO is the drug of choice, widely used, for induction and maintenance of general anesthesia 
in humane or in the veterinary medicine 7• 8l. Moreover, PRO is widely used for sedation in the 
intensive care patients 9l. PRO avoids the residual sedation, fatigue (minimal "hangover 
effect") and cognitive impairment of others sedative-hypnotic drugs. 
PRO being extensively (98%) bounds to serum/plasma proteins and appreciably 
associated with or enters the blood erythrocytes as well as 10l. Structurally, PRO is similar to 
a-tocopherol with a phenol group so it has been implicated as having antioxidant roles 11 l. The 
previous studies reported that PRO can protect the thymocytes and erythrocytes from 
peroxinitrite, protects the lipid against peroxidation 11 • 12l and macrophages from nitric oxide 
induced damage 13l, therefore inducing or maintaining agent for patients undergoing 
orthopedic surgery 14l. Apan et al. were suggested that PRO has antibacterial effect especially 
when used in combination with the ultra-short synthetic opioid remifentanil (REM) 15l. After 
receiving a single i. v. dose of PRO, the patient loses his consciousness within 30-50 seconds 
and remains unconscious for about 4-6 min 16• 17l. 
The rapidity in PRO onset and offset when used as a continuous i. v. infusion gave the 
possibility to awaken a sedated patient within minutes for evaluation and return him to sleep in 
seconds 18l. PRO is the anesthetic of choice for ambulatory surgery in outpatients related to its 
rapid onset and recovery after anesthesia. Moreover the low incidence of postoperative nausea 
and vomiting which is a very common side-effect after inhalational or balanced anesthesia 5• 19l. 
Also PRO was shown to be a potent anticonvulsant that sometimes was effective in status 
epilepticus refractory to other agents 5l. The antiemetic, antipruritic, antiepileptic effects of 
PRO are achieved at lower doses (below 0.5 µg/mL) than those required for anesthesia 20l. 
18 
Furthermore, the capability of PRO to associate with the potent, rapid and ultra-short-acting 
synthetic opioid analgesics (such as alfentanil and its congeners) has been promoted the 
successful and safe using of TIVA 21 ). Todays (especially in the big countries), PRO usage 
became widespread as it has the unique pharmacological and PK properties than other the 
convenient used hypnotics lacked. 
Mechanism of action of PRO 
The mechanism of action of PRO involves a positive modulation of the inhibitory 
function of the neurotransmitter GABA through GABAA. PRO has also been reported to 
block Na+ and Ca2+ channels, nicotinic receptors, the N-methyl-D-aspartate receptor, and 
activates the rectifying outward K+ currents. In this respect and by the way, the mechanisms 
of PRO's activity resemble to some extent those of carbamazepine (CBZ), and this effect may 
result in PRO's action on seizure duration 22). A deeper and more discussion details for 
understanding the mechanism of action and structure-activity relationships of PRO was 
pointed in a review prepared by Ttapani et al. 5l. 
PK of PRO 
The PK of PRO is best described on the basis of three compartment model (Table I) 
17, is, 23-25 l. The short effect-site equilibration half-life (T112) and the small central compartment 
are responsible for its time peak effect of only two minutes. The larger volume of distribution 
(Yd), combined with a clearance (Cl) that equals hepatic perfusion, are associated with a 
context sensitive half-time (describes the time taken for concentration in plasma of a drug to 
decline by 50% after the steady state of infusion) that only increases from about 20 to about 
30 min with infusion durations increasing from 2 to 8 hours. Consequently, PRO is very well 
suited for continuous infusion administartion. As well as, its high Cl and redistribution allow 
for a rapid return to the consciousness even after many hours of anesthesia 26• 27). 
19 
PRO is a weak organic acid that remains entirely unionized at pH 7.4. Therefore, 
PRO bounds to plasma proteins especially to albumin 28>, as mentioned before. Also 
hemoglobin has been shown to bind PRO, however its binding properties on the erythrocytes 
and serum proteins remain to be precisely qualified 29l. Although PRO is extensively bound to 
the plasma proteins, this does not seem to inhibit its rapid Cl and extensive tissues distribution. 
Table I. Pharmacokinetic and pharmacodynamic parameters of PRO and the four commonly opioids 
used with PRO 27l. 
"P~~ 
Vd1,L 4.3 8.9 5.1 8.9 14.3 
Vd2, L 24.0 50.3 9.0 13.8 63.l 
Vd3, L 238.0 296.0 6.5 12.1 262.0 
Cli , L/min 0.7 0.6 2.5 0.4 0.9 
Cli , L/min 1.6 4.8 1.7 0.9 1.6 
Cli, L/min 0.8 2.2 0.1 0.2 0.3 
T112, keO, min 2.4 4.7 0.9 1.1 5.8 
EC50, µg/L 340.0b 1.1 c 4.7c 90.oc 0.1 c 
A Model estimation for patient 40 years, 180 cm and 80 kg; b for loss of consciousness; c optimal 
EC50 in the presence of PRO; Cl1= elimination clearance; Ch= rapid distribution clearance; Ch= slow 
distribution clearance; ED50= median effective concentration for loss of consciousness (PRO) or 
adequate analgesia (opioids); T112, keO= effective equilibration T112; Vd1= volume of central 
compartment; V d2= volume of rapid equilibrating peripheral compartment; V dJ= volume of slow 
equilibrating peripheral compartment. 
Various PKs parameter sets are available in the literatures for all of these agents, but 
population PK data are available only for PRO, REM and alfentanil. These population PK 
parameter sets may therefore be best applicable in a population that varies greatly in age, 
weight, and gender 27l. 
Metabolism of PRO 
PRO is rapidly metabolized in the liver by conjugation to glucuronide and 
sulphate to produce water-soluble compounds, which are excreted by the kidneys. CYP2B6 
and CYP2C9 are predominantly involved in the oxidation of PRO 30l; other isoforms such as 
CYP2A6, CYP2C8, CYP2C18, CYP2C19 and CYP1A2 are also contributed at its high 
concentrations 31 l. 
20 
In human, PRO metabolism consists of direct conjugation of PRO to PRO-
glucuronide or conjugation of the hydroxylate metabolite (2,6 diisopropyl-1-4-quinol) to 
three metabolites, 1-quinol glucuronide, 4-quinol glucuronide and 4-quinol sulphate as 
shown in Figure 2 32l. About 90% of an injected dose of PRO is eliminated in urine in the 
form these four conjugated metabolites 33). 
~~;1 
OH OH 0 
CH3 CH3 
COOH 




diphosphate (UDP) PRO-glucuronide 
glucuronosyltransferases 
~hasell 
4-(2,6-diisopropyl- l ,4-quinol )-sulphate 




1-(2,6-diisopropyl- l, 4-quiniol)-glucuronide 
dVO 
OH OH 
4-(2,6-diisopropyl- l ,4-quiniol)-glucuronide 
Figure 2. The main metabolic pathways of PRO in human 32l. 
Side Effect of PRO 
Although PRO offers many advantages than other hypnotics, but is not free from the 
adverse side effects as has been reported 34>: 
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a) The inhibition ofCYP2Al, CYP2C9, CYP206 and CYP3A4 activities 31 ). 
b) Induction of a marked loss of sympathetic tone in healthy volunteers, lead to a 
hypotension mediated by an inhibition of the sympathetic nervous system. the 
impairment of the baroreflex regulatory mechanisms and loss of vascular tone in 
arteries, as a result of a reduced Ca2+ influx, may also contribute to the hypotension 
following induction with PRO 35). 
c) A significant reduction in the cardiac, sympathetic baroslopes and cardiac muscle 
contraction as a result of reduced free systolic Ca2+ concentration in myocardial cells 
resulting in a negative inotropic state of the cardiac muscle. 
d) PRO (even at low doses) depresses the ventilatory response to acute hypoxic incidents 
36)_ 
e) PRO infusion syndrome (especially in the children and small laboratory animal), that 
is acute refractory bradycardia leading to asystole, in the presence of one or more of 
the following: metabolic acidosis, rhabdomyolysis, hyperlipidemia, and enlarged or 
fatty liver and finally death 37• 38). 
These adverse side effects of PRO are responsible on the severe hemodynamic 
changes and respiratory depression 27). 
Dosage form of PRO 
PRO is highly lipophilic drug, that it was initially formulated in some surfactants, 
which led to a pain at the site of injection and in some cases anaphylactic reactions were 
reported. The recent dosage form of PRO is formulated as oil/water emulsion consist of soya 
bean oil, glycerol and purified egg phosphatide (Diprivan®, Zeneca UK) as 200 mg/20 mL 
ampules for direct i. v. infusion 5). 
22 
II. OPIOIDS AND ANESTHESIA 
Opioid is the term used broadly to describe the compounds that work at the opioid 
receptors in the body. PRO-opioid together with the recent i. v. administration devices (such as 
TCI) improved the anesthetic depth monitoring and optimized the administrated doses. For 
more details, Lichtenbelt el al. were described the strategies of using of PRO-opioids in 
general anesthesia in different situations 27>. 
Mechanism of Action of Opioids 
Opioids and endogenous opioids activate presynaptic receptors on GABA neurons. 
The varying effects of opioids may therefore be related to varying degrees of affinity for 
various opioid receptors. In terms of pharmacodynamics, both opioids and PRO act on y-
GABA receptors. The reason for the lower dose of PRO required for sedation in the presence 
of opioids may be due to this synergic effect. 
PK of Opioids 
Opioids differ in their PKs but, acting at similar receptor sites and exhibit comparable 
PKs. Table 1 gives an overview of representative PKs parameters of the commonly four 
opioids used with PRO in general anesthesia. The context sensitive half time of the four 
opioids gives an indication of the suitability of these agents to be given by prolonged infusion. 
Remifentanil (Ultiva®) 
REM (a hydrochloric salt of 3-[ 4-methoxy-carbonyl-4-[( 1-oxopropyl)phenylamino ]-
1-pipridine ]propanoic acid methyl ester, Figure I), is a ultra-short-acting synthetic opioid 
which has a rapid onset (1 min) and offset (15 min) after an i. v. infusion regardless of the 
duration of its infusion 39>. 
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REM remains entirely unionized at pH 7.4; it extensively (70-80%) bounds to plasma 
proteins especially to a1-acid glycoprotein. The metabolism of REM in the body is completely 
different than other opioids used in anesthesia, as it is metabolised mainly by cholinesterases 
which found in the blood plasma and tissues. REM metabolite has minimal ( 4,600 times less 
potent than REM) analgesic activity and excreted by the kidneys, Figure 3 40· 41 l. 
N-dealkalyation metabolite 
Figure 3. The main metabolic pathways of REM in human. 
The action of REM is not extended in patients with renal failure. Moreover, there is 
no risk for drug accumulation even after long-term infusion. By the way, the most attractive 
characteristic of REM is that, within the dose ranges studied thus far, recovery is not 
dependent on the infusion rate used to maintain anesthesia, the cumulative dose of REM 
administered, or the length of the procedure. The actual dose does not need to be adjusted for 
age, weight, gender, or the presence of hepatic or renal dysfunction. Therefore, REM may be 
described as the most "forgiving" opioid. 
24 
The anesthesia community has, in general, agreed that its properties of rapid and 
pleasant emergence with fewer emetic symptoms make the additional costs worthwhile. As 
the importance of REM in anesthesia procedures, many reviews outlined the REM's clinical 
pharmacology and its applications in anesthesia 40• 42-51 >. REM is very much alike other opioids 
pharmacodynamically; it produces the physiological changes consistent with potent µ-opioid 
receptor agonist activity, including analgesia and sedation with the adverse effects include, 
ventilatory depression, nausea, vomiting, muscular rigidity, bradycardia and pruritus 27>. REM 
appears to be an ideal narcotic analgesic used for TN A in combination with PRO, because of 
its independent pathway from that of PRO as well as its rapid elimination and favorable 
controllability. Therefore, the general anesthesia using PRO and REM is a very accurate, easy 
and predictable (or titratable) technique and has many advantages 52> such as: 
a) Achievement of the steady state rapidly due their rapid onset as well as a short context 
sensitive half-life. 
b) Hemodynamic stability. 
c) Rapid recovery even after Jong time of anesthesia. 
d) Lower incidence of postoperative nausea and vomiting, as PRO has antiemetic 
(potentiated with REM) properties at low doses. 
e) Patients like the sensation of waking up from a PRO infusion compared to patients 
waking up from inhaled anesthetics; those recovering from PRO feel peaceful and 
relaxed due to PRO stimulates areas in the limbic system that are related to pleasure 
(e.g. Jove, peace, relaxation and sexual content). More than 50% of the patients under 
PRO infusions have dreams; many of them report having "very nice" ones. (minimal 
hangover effect). 
f) PRO allows encephalographic and evoked potential monitoring for ischemia and 
seizures, as well as PRO and REM can be used in patients in renal failure. 
25 
The Reported PK Interaction between Pro and Fentanyl-family Opioids 
PRO and Fentanyl or Alfentanil PK Interactions: 
It was reported that, alfentanil and fentanyl affected the PK of PRO, as its V d1 and 
Cli were significantly decreased, while its V d3 was increased 24· 53· 54>. The mechanism of 
actions was suggested as the phenomena that the presence of opioid with PRO, lead to 
potentiate its hemodynamic changes or pharmacodynamically related to the GABA receptor 
activates. 
Inversely, alfentanil PKs were also altered in the presence of PRO (plasma 
concentration, 1.5 µg/mL), as a result of the inhibition of CYP3A4 which responsible for its 
oxidative metabolism. Therefore, a significant decreases in Cl 1, Ch, and Cb of alfentanil were 
resulted 53· 55-57)_ 
PRO and REM PK Interactions: 
A non-steady state (i.e. according to volunteers' demands) co-administration design 
of PRO and REM in human was used to determine their PK interactions. Through the study, 
twenty healthy volunteers initially received either PRO or REM alone in a stepwise 
incremental and decremental fashion via TCI device. The respective second drug was infused 
as a fixed plasma target concentration (0-4 µg/mL for Pro and 0-4 ng/mL for Rem). As results, 
Rem did not alter the PK of PRO, whereas PRO causes a 41 % reduction of V d1 and Cli and a 
15% reduction of the Ch of REM 58>. 
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III. EPILEPSY AND ANESTHESIA 
Epilepsy is recurrent seizures resulting from congenital or acquired factors. The term 
epilepsy is derived from the Greek word epilambanein, meaning to attack or seize 59l. Simple 
seizures involve no loss of consciousness, whereas altered the levels of consciousness are 
seen in the complex seizures 60). Epilepsy is the most common serious chronic neurological 
disorder, with a prevalence of 0.5-1 % of the population 61 ). It can be classified as generalized 
or partial seizures and either convulsive or non-convulsive in nature. Status epilepticus is a 
continuous seizure of at least 30 min duration or intermittent seizure of at least 30 min 
duration during which consciousness is not regained. Status epilepticus consider as a medical 
emergency that should be treated as quickly and aggressively as possible to prevent the 
neuronal damage. 
Antiepileptic Drugs 
The history of antiepileptic drugs (AEDs) is starting with the use of bromides in the 
1850s, phenobarbital, and phenytoin in the first half of the 20th century. The 1960s and 1970s 
saw sodium valproate (valproate) and CBZ become the standard treatments for epilepsy, and 
they still are. Also, PRO and a short acting benzodiazepine, midazolam (MDZ) are used in the 
clinical practice for the treatment of generalized seizures and status epilepticus 62). 
Mechanism of Action of AEDs 
In simple terms, a seizure can be seen as the result of imbalance between excitatory 
and inhibitory neuronal activity. This leads to the generation of hyper-synchronous firing of a 
large number of cortical neurones. Traditional AEDs exert antiseizure activity by the 
following mechanisms 61 ): 
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a) Reduce the inward voltage-gated positive currents (Na+ and Ca2+). 
b) Increase inhibitory neurotransmitter activity (GABA). 
c) Decrease excitatory neurotransmitter activity (glutamate and aspartate ). 
In terms of pharmacodynamics, valproate and PRO act on GABA receptors. The 
reason for the lower dose of PRO required for sedation in the presence of valproate 63). In in 
vitro and in vivo studies, valproate were reported to inhibit CYP2C9 22• 64) and UDP-
glucuronosyltransferase 1A9 enzyme system that is essential in the metabolism of PRO 65>. 
Additionally, valproate increases the rate of protein unbound free PRO in human serum, 
which results in an increase in sedative effect due to the free PRO 66). 
Carbamazepine (Tegretol®) 
CBZ (SH-dibenz[b,f]azepine-5-carboxamide, Figure l) is a dibenzazepine, tricyclic 
drug used for the treatment of epilepsy, trigeminal neuralgia, and schizophrenia 67-69}_ It has 
been the first choice as AED for the wide range of seizure disorders in both adults and 
children due to its efficacy and acceptable safety profile 70). 
CBZ the main mechanism of its anticonvulsant effects through inhibit the Na+ 
channel activity 71 >. Unfortunately, CBZ plasma concentrations are closely related to its 
curative effect and toxic side effects. Therefore, it is necessary to monitor its plasma 
concentrations to improve the curative effect and decrease the expected toxic side effects after 
long term of administration 72-75>. 
Unlike valproate, CBZ is an inducer for several potential pathways of drug 
elimination, including CYPs, as well as the active transporter P-glycoprotein. To our 




CBZ absorption following an oral administration has been shown to be slow, 
changeable, unpredictable, but almost complete with approximately 80-90% bioavailability 76). 
Peak plasma concentrations are usually observed between 2 to 6 hours following oral 
administration 77• 78). CBZ is rapidly distributed into all tissues and fluids throughout the body 
and is reported to have V d of approximately 1-2 L/kg. 
The dose of CBZ should be adjusted to the needs of the individual to achieve 
adequate control of seizure activity without the toxic side effect. From the literatures, the 
effective total plasma concentration of CBZ is approximately 4-12 µg/mL for daily divided 
doses of 400 to 1200 mg 78>. CBZ highly (70%) bounds to plasma proteins especially to 
albumin and a-acid glycoprotein 79>. 
Metabolism of CBZ 
CBZ is mainly metabolized in the liver with approximately 5% of the drug excreted 
as un-changed 80>. The hepatic metabolism of CBZ is catalyzed by CYP3A4, CYP2C8 and 
CYP3A5 isoforms to an active metabolite (10,11-epoxide). This active metabolite is further 
deactivated by the action of epoxide hydro lase to give inactive I 0, 11-CBZ-diol that is 
excreted as glucuronides conjugates by the kidneys as shown in Figure 4 81 • 82>. 
CBZ I 0, 11-CBZ epoxide 
Figure 4. The main metabolic pathways ofCBZ in human. 
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Figure l) is a short-acting imidazobenzodiazepine with hypnotic, muscle-relaxant, 
anticonvulsant, and anxiolytic properties. It is used for the induction of anesthesia, sedation 
and the treatment of generalized seizures and status epilepticus 83l. 
Mechanism of Action of MDZ 
MDZ binds with GABAA receptor in the CNS leads to its activation to the 
neurotransmitter GABA; therefore, an indirect enhancing of the inhibitory action of GABA 
occurs. Santhosh et al. was reported that the enhancement of the inhibitory action of GABA 
may enhances both the CNS and respiratory depressant effects of PRO when combined with 
benzodiazepines 84l. 
PKofMDZ 
Following an oral administration, MDZ is absorbed rapidly from the gastrointestinal 
tract with maximum plasma concentration occurring usually within 30-90 min. but following 
an i. v. administration, the onset of action occurs rapidly within 1-5 min. MDZ has a V d of 1-
2.5 L/kg in normal healthy volunteers. MDZ extensively (96%) bounds to plasma proteins 
especially to albumin 85l. 
Metabolism of MDZ 
MDZ is metabolised mainly by the hepatic CYP3A3 isoform to an active metabolite 
l '-hydroxy-MDZ, as it's the main metabolite. Other minor pharmacologically inactive 
metabolites such as 4-hydroxy-MDZ and I' ,4-dihydroxy-MDZ are also produced. All these 
metabolites undergo to rapid glucuronidation and then excretion by the kidneys, as shown in 
Figure 5 83l. 
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Compared with other benzodiazepines, MDZ has a short elimination T1 12 of 1.5-3 h 
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From the literatures, MDZ is neither inhibitor nor inducer of CYP3A4 metabolism, 
however it has been proposed for the hepatic CYP3A phenotyping (assessing the functional 
CYP3A activity). MDZ is widely used probe in drug-drug interaction research to predict the 
enzyme inhibition or induction or to predict the unwanted therapeutic outcomes such as lack 
of therapeutic efficacy or potentially harmful response. 
31 
Since 2003, MDZ is recognized as one of the preferred in vivo probes by food and 
drug administration (FDA) and the pharmaceutical research and manufacturers 86l. 
PRO and MDZ PK Interactions 
The PK interactions between PRO and MDZ have been studied extensively 54• 87• 88l. 
Briefly, the blood concentration of PRO was significantly increased (25%) in the presence of 
co-administrated MDZ, related to the hemodynamic changes or pharmacodynamically both 
drugs act on GABA receptors. That resulted in the common phenomena that the combination 
between PRO and benzodiazepines may enhances both the CNS and respiratory depressant 
effects of PRO 54• 89l. The plasma concentration of MDZ was also increased in the presence of 
PRO (at plasma concentration, 1.2 µg/mL) as a possible competitive inhibition of CYP3A3, 
CYP3A4 and CYP3A5 isoforms responsible for MDZ metabolism 87• 88) by PRO. 
PRO and CBZ expected PK Interactions 
As mentioned before, CBZ has a fairly narrow therapeutic range which can produce 
numerous of the adverse effects. CBZ is an inducer for several potential pathways of drug 
elimination, including CYPs such as CYPIA2, 2C9, and 3A4, as well as the active transporter 
P-glycoprotein. Therefore, a drug such as PRO, undergoes metabolism via these CYPs is 
likely to be affected after CBZ co-administration. 
In addition to CBZ is primarily metabolized by CYP3A4 to an active metabolite that 
has about the same efficacy as the parent compound. Therefore, a drug such as PRO has an 
inhibition for CYP3A4 will expected to decrease the hepatic metabolism of CBZ and lead to 
its accumulation with the signs of toxicity 9o, 91 l. 
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IV. REPORTED ASSAY METHODS FOR PRO, REM, MDZ AND CBZ 
Recently, an analytical review has been published to summanze the reported 
important analytical methods for determination of PRO in the different biological fluids 34)_ 
Since PRO binds tightly to erythrocytes (:::::50%) 92l, therefore the whole blood is preferred for 
the analysis of PRO and its metabolites for PKs or forensic studies. 
The majority of these methods were used HPLC-UV, -fluorescence, or -
electrochemical detections 9• 93-103)_ HPLC-UV methods (at a wavelength of 270 nm) for its 
determination in human plasma 104-106), blood 96• 97• 99l, serum 107• 108) or urine 32• 104• 106• 109l; dog 
plasma 110l , blood 99l, or rat blood 98l have been reported. LC-MS/MS methods have been 
used to determine PRO either by atmospheric-pressure chemical ionization without 
derivatization 111 l; or by negative electrospray ionization (ES!") with 102• 103l or without 112l 
derivatization in human plasma, blood and serum 103• 111 • 112l, or in rat plasma and blood 102l. 
REM contains a methyl ester group in its structure, which makes it not only 
susceptible to enzymatic hydrolysis but also to chemical hydrolysis at physiological pH. 
Consequently, the addition of an acid to the collected blood after administration (citric acid 
(20 µL, 50% w/w)/mL of the collected blood 113l) was needed to prevent the both types of 
hydrolysis 114• 115l. 
Clinically, REM plasma concentration is 1-40 ng/mL, that is achieved after an 
infusion rate of 0.04-2 µg/kg/min 116l. Because of these circumstances (REM's instability and 
low plasma concentrations), measurement of REM concentrations in the circulation is 
challenging. Most of the reported methods determined REM in whole blood which preferred 
to avoid time spent on plasma preparation. 
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Several HPLC-UV methods (at a wavelength of 210 nm) were developed in human 
plasma 110l and blood 98• 99• 114• ll 6-121 l, dog plasma and blood 99• 110l and rat blood 98• 114• 121 l. 
Other sensitive LC-MS/MS methods for REM analysis in plasma 115• 122l, blood 123l, and urine 
124l have been reported. 
As mentioned before, monitoring the concentration of CBZ in human plasma is a 
great importance to clinical analysis. Hence, several publications deal with the determination 
of CBZ in different biological samples. HPLC-UV methods (at a wavelength of285 nm) were 
reported for CBZ and its metabolite determination in human whole plasma 125-134l, blood 135l, 
serum 136-139l, urine 127l and saliva 128l or in rabbit plasma 140l . Other techniques such as liquid 
chromatography-mass spectrometry (LC-MS) 73• 135• 141 • 142l and LC-MS/MS 73• 142• 143l have 
been reported. 
Benzodiazepines are commonly administered with a potential of abuse and an 
environmental pollution 144l. Several non-chromatographic techniques are available for their 
rapid analysis in plasma, blood, or urine. These assays were depended on the available 
laboratory kits that are often used to provide an initial test for the enzyme immunoassay 
determination 145l and linked immunosorbent assay 146l. Moreover, many analytical reviews 
have been published to summarize the most important reported chromatographic separations 




DEVELOPMENT AND VALIDATION OF AN HPLC-UV 
METHOD FOR SIMULTANEOUS DETERMINATION OF 
PROPOFOL AND REMIFENTANIL IN RAT PLASMA 
1.1. BACKGROUND 
As mentioned before, PRO and REM are the drugs of choice, commonly co-
administered in TIV A 149, 150>. A little is known about PRO and REM PK interactions after co-
administration. Overdosing of PRO or REM in TIV A causes cardiovascular depression as 
manifested by symptoms such as severe bradycardia and asystole 151 >. Clinically, REM 
decreases the concentration of PRO required for loss of consciousness 152>, because they 
interact pharmacodynamically and act synergistically in response of hypnosis and nociception 
153>. The aim of the present study was to develop a simple and rapid HPLC-UV method for 
simultaneous determination of PRO and REM to investigate their PKs drug-drug interactions 
in rat plasma following co-administration by i. v. infusion. 
1.2. MATERIAL AND METHODS 
1.2.1. Reagents and Standards 
PRO, sodium carbonate, sodium hydrogen carbonate, ammomum acetate, 
ethylacetate, hexane, ibuprofen (IBU), clonidine (CLO), methyl eugenol, methyl phenol, 4-
methoxyactophenone, 2,6-di-tert-butyl-4-methyl phenol, 2,6-xylenol, t-butyl methyl ether (t-
BME), diethyl ether, heptane, and acetonitrile were obtained from Wako Pure Chemicals, Ltd. 
(Osaka, Japan). REM hydrochloride was obtained from Janssen Pharmaceuticals, Inc. (Tokyo, 
Japan). Fluoxetine (FLU) was purchased from Sigma-Aldrich (Steinheim, Germany) and used 
as IS. All other reagents were of analytical reagent and LC grade. Water was deionized and 
distilled by an Aquarius GSR-500 automatic water distillation apparatus obtained from 
Advantec (Tokyo). Nitrogen gas of 99.999% purity was provided by Daiichisanso (Nagasaki, 
Japan). 
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1.2.2. Standard Solutions and Quality Control Samples 
The stock standard solutions of PRO, REM and IS were prepared by dissolving 
accurately weighed individual compounds in acetonitrile to give a final concentration of 1 
mg/mL (REM base was prepared by accurately weighing 1.1 mg of REM hydrochloride 
(equivalent to 1 mg of the free base)). Then the solutions were serially diluted with 
acetonitrile to obtain the working solutions at concentration range over 25-2500 ng/mL for 
both PRO and REM and 1 µg/mL for the IS. All the solutions were stored in a refrigerator at 
4°C and brought to room temperature (25°C) before use. 
The analytical standard and quality control (QC) samples were prepared by blank rat 
plasma (200 µL) spiked with standard working solutions (20 µL) during the study of method 
validation. The calibration samples were made at six calibration points of concentrations of 
25, 50, 100, 500, 1000, and 2500 ng/mL for both PRO and REM while their QC samples were 
prepared at concentrations of 50, 500, and 2500 ng/mL. 
1.2.3. HPLC-UV System and Conditions 
The chromatographic separations were performed on an HPLC system, consisted of a 
Shimadzu LC-lOATvp LC pump (Shimadzu, Kyoto, Japan), 7125 injector with a 20-µL 
sample loop (Rheodyne, CA, USA), equipped with a 10 µL loop Shimadzu SPD-1 OA variable 
wavelength UV detector that set at 210 nm. 
The separation was performed by using a Chromolith Performance RP-18e ( 100 x 4.6 
mm i.d., Merck Darmstadt, Germany); with a gradient elution program with mobile phases: A 
(acetonitrile) and B (ammonium acetate buffer, 10 mM, pH 5.8). The gradient program was: 
75% of mobile phase B for 3 min, followed by stepwise gradient from 75% to 60% until 8 
min, changed to 55% until 11.8 min. the washing step by 100% mobile phase A until 15 min 
and then return to initial condition after 20 min. 
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The mobile phases were filterted through (0.45 µm nylon membrane (Omnipore™, 
Millipore, Tokyo), degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai)), and 
pumped into the column at a flow rate of 1.5 mL/min. A summary of the HPLC conditions is 
shown in Figure 6. 
Column: Chromolith Performance RP-18e (100 x 4.6 mm i.d.). 




Detector: Shimadzu SPD-1 OA. 
Detection wavelength, A.: 210 nm . 
Mobile phases A (acetonitrile) and B 
(ammonium acetate buffer (10 mM, pH 
5.8)), were eluted according to gradient 
program. 
• Flow rate: 1.5 mL/min. 
• Injection volume: 20 µL. 
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Figure 6. HPLC conditions and the gradient elution program. 
1.2.4. Plasma Collection 
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The plasma samples used in the present study were obtained from male Wistar rats 
(n=3, weight 250-320 g) purchased from Kyudo Experimental Animal (Saga, Japan). The rats 
were housed in the conditions of constant temperature (24°C) and provided with standard 
laboratory food (Oriental yeast, Tokyo) and water ad libitium. All animal procedures and care 
in this experiment were permitted by Nagasaki University animal care use committee (NO. 
1406021153). The rats were anesthetized with ethyl carbamate (1.5 g/kg, intraperitoneal, i.p.). 
A cannula was inserted into the femoral artery of the rat for blood withdrawal. The 
blood samples were collected into eppendorf tubes contains ethylene diamine tetraacetic acid 
disodium salt (EDTA.2Na, 1.0 mg/mL of blood). The collected blood was centrifuged 
(2000g) for 10 min at 4°C, and the obtained plasma were kept at -30°C prior to use. 
39 
1.2.5. Plasma Pre-treatment 
To 200 µL of rat plasma was spiked with 20 µL of PRO and REM mixture and 20 µL of 
IS (Stock solution concentrations in acetonitrile was I I. I µg/mL ), vortex-mixed for I 0 sec. 
One hundred-micro liter of sodium carbonate buffer (I 00 mM, pH I I .2) was added and vortex-
mixed for 30 sec, followed by addition of 700 µL of hexane for liquid-liquid extraction (LLE) 
procedure. Vortex-mixed for 60 sec, then the mixture was centrifuged (2000g) for IO min at 
4°C. Six hundred-microliter of the supernatant was transferred to another vial and evaporated 
to be dryness under a gentle stream of N2 gas. The residue was reconstituted with 30 µL of 
mobile phase and then 20 µL of reconstituted volume were injected onto the column for 
analysis. Triplicate measurements for each sample were performed as the amount indicated as 
means± SD. The summary of the pre-treatment procedure illustrated in the Figure 7. 
Plasma, 200 µL (or+ standards, 20 µL) 
f carbonate buffer (100 mM, pH 10), 100 µL 
Vortex-mix for 30 sec r LLE, Hexane, 700 µL 
Vortex-mix for 60 sec 
Centrifuge (2000g) at 10°C for 10 min 
i 
Take supernatant, 600 µL 
• Dry under N at 25°C t Reconstitute with acetonitrile, 50 µL 
Sample solution for HPLC analysis, 20 µL 
Figure 7. Pre-treatment procedure of PRO and REM in rat plasma for HPLC-UV method. 
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1.2.6. Method Validation 
The method was validated for selectivity, calibration curves linearity, limit of 
detections (LODs), limit of quantifications (LOQs), accuracy, precision and recovery after 
extraction from plasma. 
The selectivity was investigated by preparing and analyzing three of individual rats' 
blank plasma samples at the LOQs to check any interference at the retention time of the 
analytes. 
The calibration curves linearity were assessed by preparing and analyzing the blank 
rat plasma spiked with PRO and REM standard of known concentrations (over the range of 
25-2500 ng/mL with six spiked concentration points); triplicate measurements for each 
concentration were performed. The LOO was estimated as the amount of PRO or REM, 
which caused a signal three times to peak height of the blank response (noise). The LOQ was 
defined as the lowest concentration on the calibration curves of the analytes measured with 
acceptable precision and accuracy and with at least ten times compared to the plasma blank 
noise peak height. 
The accuracy and precision were assessed by determining the QC samples at three 
concentration levels (three samples for each concentration) on the five different validation 
days. The accuracy was expressed as a percentage of the measured concentration over the 
nominal (theoretical) concentration and the precision was determined as the RSD%. The 
criteria used to assess the suitability of precision as the RSD% did not exceed 15%; and the 
accuracy was within 20% of the actual value 154• 155>). The recovery (extraction efficiency) of 
analytes from rat plasma after the extraction procedure was determined by comparing the 
areas of extracted analytes with those of the non-extracted pure standards that represent 100% 
recovery. 
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1.3. RESULTS AND DISCUSSION 
1.3.1. Optimization of the Assay Conditions 
Following to sample preparation, an instrumental analysis should be effective to 
isolate the analytes of interest in biological sample from interfering compounds. 
Chromatography is based on the separation of analytes of interest in a mixture due to the 
differing time taken for each analyte to travel through a stationary phase which carried 
through it by a mobile phase. The main component and consider as the heart of any HPLC 
system is the column which can be described by its dimensions and particle size. Reversed 
phase (RP) column is considered the column of choice for HPLC analysis 156l, because it 
provides a compatibility with aqueous and organic solutions as well as with different 
detection systems. However, the disadvantages of RP columns such a slow mass transfer and 
limitations caused by column back pressure, could be overcame by introducing the monolithic 
columns 157l. 
The Monolithic columns are porous rod structures characterised by mesopores and 
macropores. These pores provide the monolithic column with high permeability, a large 
number of channels and a high surface area available for reactivity. The macropores 
dramatically reduce the column back-pressure and allow the use of faster flow rates, thereby 
reducing the analysis time 158>. While monolith is a popular material for chromatographic 
columns fabrication, it also plays a role in SPE sample preparation 155• 159>. The details of the 
miscellaneous applications of monolith are reviewed in a series published by Svec 160-162>. In 
the present thesis a monolith silica-based column (Chromolith® Performance RP-18e (100 x 
4.6 mm i.d., Merck, Darmstadt, Germany)) was utilized for the chromatographic separations. 
Recently, mixed-mode columns were introduced to provide a practical solution to the 
selectivity challenge with RP and monolithic columns. It combines both RP and ion-exchange 
retention mechanisms. 
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The presence of both RP and ion-exchange functionalities eliminates the need for ion-
pairing agents in the mobile phase, making it compatible with mass spectrometry (MS) 
detections 163• 164l. Unfortunately, the combination between RP, anion, and cation ligands 
perhaps is the major drawback for these types of column. As the strong ionic interaction of 
this stationary phase with biological matrices (some of these components present in a highly 
concentrations) lead to increase the time of separation and additionally a washing step after 
the analyte separations is needed. This issue can be resolved by increasing the ionic strength 
of aqueous part (buffer) in the mobile phase. However, it is important to mention that the 
percentages of acetonitrile higher than 50% led to precipitation of highly used salt (in buffer 
phase), and the low percentages of acetonitrile likely affects the elution of highly hydrophobic 
compounds from the column 165l, 
As the difference in the structure of PRO (acidic analyte) and REM (basic analyte), 
therefore we speculated, the separation by using a multimodal Scherzo SM-C18 (150 x 2 mm 
i.d., 3 µm, Imtakt Co., Kyoto) are going on easily. An isocratic mobile phase consist of 
acetonitrile-ammonium acetate buffer (10 mM, pH 6) was studied using IBU as an IS. 
The preliminary experiments were directed toward the effect of various variables on 
the chromatographic system suitability for the standard analytes separations. The parameters 
which assessed involved the type and percentage of the organic modifier, concentration of 
ammonium acetate buffer as well as its pH as shown in Figure 8A-C. Under these conditions 
the retention time (using Scherzo column) of PRO, REM and IS, respectively was 10, 6 and 8 
min. 
The plasma samples preparation were tried with protein precipitation, LLE, and 
hybrid of protein precipitation and LLE. SPE procedures using monolithic (MonoSpin), 
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Figure 8. Study of acetonitrile content (A), ammonium acetate buffer concentration (B) and its pH (C) 
in mobile phase on the retention time and peak heights of the analytes. Sample: standards concentration, 
50 ng/mL for PRO and REM, IS (lµg/mL). The optimal conditions were selected as the arrows 
referred. 
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For this type of column the washing step is much necessary to elute the latent plasma 
peaks after analytes elution as mentioned before. Unfortunately the column washing was 
extended for long time (~ 60 min) between each separation. Therefore, modifications in the 
HPLC-UV system and conditions were occurred by adding another pump (Shimadzu LC-
1 OATvp LC) to deliver the washing solution. Among the different washing solutions which 
used were acetonitrile-acetate buffer (50 mM, pH 3.5) (=70:30%, v/v); acetonitrile-
isopropanol-water (=50:30:20%, v/v/v) and acetonitrile- tris(hydroxymethyl)aminomethane) 
buffer (100 mM, pH 7.5). As the results, the trials to optimize the Scherzo column's washing 
step were unsatisfactory, and affected the experimental rapidity and reproducibility. Therefore, 
to complete the research point, a monolith-C18 column (Chromolith (100 x 4.6 mm i.d.) was 
preferred instead the Scherzo SM column. 
As the presence of a suitable IS with the analytes mixture is much important during 
HPLC analysis, to minimize the experimental errors; analytes such as IBU, methyl eugenol, 
methyl phenol, 4-methoxyactophenone, CLO, 2,6-di-tert-butyl-4-methyl phenol, 2,6-xylenol 
and finally FLU were checked as IS. A gradient elution using FLU as an IS was needed in 
order to complete separation of target analytes from plasma samples. 
Sample preparation before instrumental analysis should effectively isolate the 
analytes from the matrix interfering compounds 166• 167>. However, it is a bottle-neck and 
consume about 80% of the analysis time 168>. The samples free from interfering matrices not 
only simplify analysis but also maximize the sensitivity of detection 169>. LLE is the traditional 
procedure for sample preparation in bioanalysis 110>. 
The principle behind the separation is the distribution of sample components between 
two immiscible liquids. The main advantages of the LLE procedure are: large samples 
capacity, clean extracts, and an easy approach to sample concentration. 
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The plasma samples in the present study were treated by a LLE as described 
previously, and the representative chromatograms for rat plasma blank and that spiked with 
analytes are showed in Figure 9. 
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Figure 9. Chromatograms of drug free rat plasma (A) and that spiked with PRO, REM, and IS (B). 
Sample: spiked concentration, 50 ng/mL for PRO and REM and 1 µg/mL for IS (standard solution, 
11 .1 µg/mL in acetonitrile ). 
1.3.2. Method Validation 
1.3.2.1. Selectivity 
The selectivity of the proposed method was tested by analyzing different rat plasma 
blank for any interference. As the chromatogram of plasma blank extract and that spiked with 
the analytes were shown in Figure 9 there are no interfering peaks at the retention time of the 
all analytes. The retention time for REM, IS and PRO was 2.9, 7.9 and 12.0, respectively. 
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1.3.2.2. Linearity, LODs and LOQs 
The calibration curves were constructed in rat plasma in the concentration ranges of 
25-2500 ng/mL (six calibration points, 25, 50, 100, 500, 1000, and 2500 ng/mL) for PRO and 
REM. The analyte on IS peak area ratios were found to have acceptable linearity with the 
selected concentration range as indicated by acceptable correlation coefficients ((r) ~ 0.983). 
The calibration curves' equations for PRO and REM respectively were; y = 0.002x - 0.060 
and y = O.OOlx - 0.030 (where, y =peak area ratio and x =the amount of the analyte, ng/mL). 
The LODs and the LOQs were defined as the concentration giving peak height at a signal-to-
noise (SIN) ratio of 3 and 10 were 3 and 10; 6 and 20 ng/mL, for PRO and REM respectively. 
The recoveries of analytes from rat plasma after the extraction were 88.3±7.6 and 68.7±5.5 as 
the average of low, middle, and high concentration levels for PRO and REM respectively as 
shown in Table 2. 
1.3.2.3. Accuracy and Precision 
The accuracy of the proposed method was estimated by comparing the measured 
(calculated) concentrations of PRO or REM in the plasma with the nominal (theoretical) 
concentration values of the standard in the mobile phase. The calculated accuracy for PRO 
and REM was found between 80.1±4.1 % and 105.3±6.8% indicating an acceptable accuracy 
for the proposed method. 
The results also showed that intra- and inter-day precisions (variations) at three 
different concentrations levels of PRO and REM were within the acceptable validated range 
as the RSD% was found Jess than 15% for intra- and inter-day precisions, Table 3. 
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Table 2. Linearity range, statistical data, and recoveries for determination of PRO and REM in spiked 
rat lasma. 
PRO 25-2500 0.997 y = 0.002x -0.060 88.3±7.6 
REM 25-2500 0.983 y = 0.001 x -0.030 68.7±5.5 
1r: Correlation coefficient 2y: Peak area ratio and x: Sample cone., ng/mL 
3Recovery vs. standard (average of low, middle, and high concentration, n=3) 
50 80.1±4.1 5.1 11.3 
PRO 500 97.3±4.9 5.0 9.4 
2500 97.5±5. l 5.2 6.8 
50 105±6.8 6.5 14.9 
REM 500 94.1±4.2 4.7 10.6 
2500 96.3±4.3 4.5 9.1 
1Accuracy % =(Found concentration/nominal concentration) x 100 
2SD = Standard division 
3RSD = Relative standard division 
1.4. CONCLUSION 
In the present work a simple and selective, HPLC-UV using a monolithic column was 
developed for simultaneous determination of PRO and REM using FLU as an IS in rat plasma. 
Unfortunately, the obtained sensitivity could not reach the clinical concentration of REM 
(plasma concentration 1-40 ng/mL) when used in clinical practices with PRO. Even the 
present sensitivity for PRO (plasma concentration is 1-4 µg/mL) was fulfill its clinical 





SIMULTANEOUS DETERMINATION OF PROPOFOL 
AND REMIFENTANIL IN RAT PLASMA BY LIQUID 
CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY: A 
PRECLINICAL APPLICATION TO PHARMACOKINETIC DRUG-
DRUG INTERACTION ANALYSIS 
2.1. BACKGROUND 
MS spectrometry is closest to being an ideal chromatographic detector; it combines 
the optimum sensitivity with the maximum identification capability. The MS is related to gas-
phase separation of ionized species according to their mass-to-charge ratio (m/z) and the 
resulting MS spectrum is a plot of the relative intensity versus m/z. The basic components of 
MS are an inlet device, ion source, ion separation system (mass analyzer, which is the "heart" 
of the mass spectrometer) and detector 17 1l. While gas chromatography (GC) can easily be 
coupled to MS, LC can only be coupled via sophisticated interfaces (probes) to remove the 
mobile phase and ionize the analyte 172). Two relatively robust LC-MS interfaces related to the 
atmospheric pressure ionization technique; electrospray ionization (ESI) and atmospheric 
pressure chemical ionization (APCI), which became the ' golden standard ' for LC-MS system. 
Although both interfaces perform what called 'soft-ionization' and generate ions at 
atmospheric pressure, each is characterised by a specific ionization mechanisms as were 
described by Bruins and Kerbarle 173• 174). ESI can be used in positive or negative polarity 
mode, dependent on the structure of the analyte of interest 174l. Mass analysis is performed 
using one or two MS analyzers (MS/MS), which consist predominantly of ion traps and 
quadrupoles, sometimes of sector field and time-of-flight instruments 175l. The analyzers can 
operate either in the full scan mode or in the more sensitive selective reaction monitoring 
(SRM) detecting positive or/and negative ions (earlier calling multiple reaction monitoring 
MRM) that is the most powerful technique for quantification of small amounts of analyte in 
complex matrices 176• 177l. The LC-MS/MS coupled on-line with ESI has been frequently used 
in PK studies 178l . In the present study the change from HPLC-UV to LC-MS/MS greatly 
achieved the challenge for determination of PRO and REM in mixture with the required 
sensitivity and selectivity. An LC-MS/MS spectrometry was developed and validated using 
CBZ as an IS . The method was successfully applied to study the PK interactions between 
PRO and REM after their co-administration by i. v. infusion to male Wistar rats. 
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2.2. MATERIAL AND METHODS 
2.2.1. Reagents and Standards 
CBZ as an IS was obtained from Sigma-Aldrich, Inc. (St. Louis, MO, USA). 
Intralipid® 10% emulsion was obtained from Fresenius SE Co. (Kabi, Tokyo) and all other 
reagents were of analytical reagent grade; as in Chapter 1. 
2.2.2. Standard Solutions and QC Samples 
The stock solutions of PRO and REM respectively, 100 µg/mL and 100 ng/mL, were 
prepared in acetonitrile, stored at 4°C in a refrigerator, and were brought to room temperature 
before use. The stock solutions were serially diluted in acetonitrile to obtain the working 
solutions at concentrations over the range of 0.27-10 µg/mL and 0.17-50 ng/mL for PRO and 
REM, respectively. The analytical standard and QC samples were prepared by spiking blank 
rat plasma (200 µL) with standard working solutions (20 µL) during study the method 
validation. For in vivo PKs study the stock solutions of PRO (10 mg/mL) was prepared in 
Intralipid® 10% emulsion and the stock solution of REM hydrochloride (10 µg/mL) was 
prepared in 0.9% saline. 
2.2.3. LC-MS/MS System and Conditions 
A Waters 2695 separation module (Waters Co., Milford, MA, USA) was used for 
solvent and sample delivery. The chromatographic separations were achieved by using a 
Chromolith Performance RP- l 8e (as described in Chapter 1) at 30°C of column temperature. 
The mobile phase was a mixture of acetonitrile-ammonium acetate buffer (10 mM, pH 3.5) 
(=90: 10%, v/v), pumped at a flow rate of 0.5 mL/min. A negative- and positive-ES! (ESI- and 
ESi+) easily changeable Quattro micro™ triple quadrupole mass spectrometer (Waters Co.) 
was used for mass analysis and detection. 
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Mass spectrometric analysis set up in the SRM mode; it was performed in a negative-
ion mode for PRO and a positive-ion mode for REM and IS. Nitrogen gas was used as 
desolvation (500 L/h) and nebulizer (50 L/h) gas. The source and desolvation temperatures 
were kept at 120°C and 350°C, respectively. The selected ESI-MS/MS parameters are listed in 
Table 4. The LC-MS/MS system was controlled by MassLynx™ V 4.0 software (Waters Co.). 
Table 4. Selected ion transitions (mass-to-charge (mlz) values) and mass spectrometric parameters for 
analysis of PRO, REM and IS in SRM mode. 
Parameters PRO REM IS 
Precursor ion, mlz 176.94 [M-H]- 377.04 [M+Ht 237.07 [M+Ht 
Product ion, mlz 160.87 317.04 220.01 
Ionization ESI- ESI+ ESI+ 
Detection mode SRM SRM SRM 
ESI Capillary voltage, kV -3 +3 +3 
Cone voltage, V -30 +15 +20 
Collision energy, eV 11 14 17 
Ion energy 1, V 
Ion energy 2, V 2 2 
Source temperature, °C 120 120 120 
Desolvation temperature, °C 350 350 350 
2.2.4. Plasma Pre-treatment 
To 200 µL of rat plasma, 20 µL of IS (spiked solution: 11.1 µg/mL in acetonitrile) 
was added and vortex-mixed for 10 sec and followed with I 00 µL of acetonitrile for 
deproteinization. One hundred-micro liter of sodium carbonate buffer (100 mM, pH 11.2) was 
added and vortex-mixed for 30 sec, followed by addition of 700 µL of t-BME for LLE. 
Vortex-mixed for 60 sec, then the mixture was centrifuged (2000g) for 10 min at 4°C. The 
supernatant was transferred to another vial and evaporated to be dryness under a gentle stream 
ofN2 gas. 
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The residue was reconstituted with 50 µL of acetonitrile and then 20 µL of 
reconstituted volume were injected onto the column for analysis. Triplicate measurements for 
each sample were performed, as the amount was indicated as means± SD. 
2.2.5. Method Validation 
The validation parameters, such as method selectivity, matrix effect (ME) and 
reproducibility, calibration curves linearity, lower LODs and the lower LOQs, accuracy, 
precision and the recovery after extraction were estimated according to the food drug 
administration (FDA) guideline for validation of the bioanalytical methods 154>. Blank rat 
plasma samples obtained from ten different rats were tested for any visible interference at the 
retention time of the analytes. The relative ME on the spectral response of PRO and REM was 
assessed as described by Abay et al. 179). In order to evaluate the absolute ME, drug free blank 
rat plasma (ten samples) was extracted with t-BME, dried and reconstituted using acetonitrile 
solutions of low (0.5 µg/mL or 1 ng/mL) and high (10 µg/mL or 50 ng/mL) concentrations 
levels for PRO and REM, respectively and at one concentration level of the IS (1 µg/mL), A. 
The standard samples which prepared in the reconstituted solution (acetonitrile) at the same 
concentrations without matrix components (pure standards) were used, B. 
The ME was calculated as the IS normalized matrix factor (IS-MF), which is the peak 
area ratio in the presence of matrix for each plasma sample (A) divided by the mean of the 
peak area ratio in the absence of matrix (B). The calibration curves were assessed by seven 
concentration points (0.27, 0.5, 1, 2, 4, 6, and 10 µg/mL for PRO and 0.17, 1, 2.5, 5, 10, 30 
and 50 ng/mL for REM) using same spiked volume 20 µL of IS. The LODs and lower LOQs 
were defined as the concentration giving peak area at SIN of 3 and 5, respectively. 
The accuracy and precision of the proposed method were assessed by determining the 
QC plasma samples spiked at three concentration levels, 0.5, 2 and 10 µg/mL of PRO and 1, 
10 and 50 ng/mL of REM (n=5). 
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The accuracy was expressed as a percentage of the calculated concentration on the 
nominal (theoretical) concentration. The intra- and inter-day precision was determined as the 
RSD%. The recoveries of analytes after extraction from plasma samples were determined by 
comparing the peak areas of extracted analytes (spiked at two concentration levels, 0.5 and 10 
µg/mL for PRO and 1 and 50 ng/mL for REM, and at one concentration level, 1 µg/mL for IS 
(n=5)) with that of the non-extracted pure standards (at the same concentration levels, n = 5). 
2.2.6. Administration Design and Sampling Time Schedule 
The administration study was performed using male Wistar rats (as described in 
Chapter 1). After the rats were anesthetized with ethyl carbamate (1.5 g/kg, i.p.); each animal 
had two indwelling cannulae: a femoral vein cannula for drug administration and a femoral 
artery cannula for blood sampling. PRO (dose; 125 µg/kg/min) and REM (dose; 125 
ng/kg/min) were administrated by the infusion route for 60 min using a microinjection pump 
(CMA/100; Carnegie Medicine, Stockholm, Sweden). Then the blood samples(::::: 0.350 mL) 
were collected at time intervals of 10, 15, 25, 30-40, 45, 50, 55, 60, and 65 min as a 5 min 
after administration stopping as shown in Figure I 0. Meanwhile a volume of 0.350 mL of 
saline was given to the rat after each sampling for keeping body balance. 
Cannula insertion in femoral 
vein for i. v. infusion Sole administration Co-administration 
Cannula insertion in femoral 
artery for blood samples 
10 
; I I I I I I 
15 20 25 30 40 45 
Time after administration, min 
I I ~ 
50 55 60 65 
Figure 10. Sampling schedule for rat plasma administrated with PRO and/or REM. 
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Each collected blood sample was added to tubes eppendorf contained EDT A.2Na 
powder as an anticoagulant for plasma preparation. To avoid REM degradation, a 30 µL of 0.2 
M citric acid were added immediately for all the collected blood samples (0.350 mL) 180). The 
plasma samples were prepared rapidly by centrifugation (2000g) for 10 min at 4°C then stored 
at -30°C until analysis. For method application into the rats, two experiments were performed. 
The first is sole administration of PRO or REM for 60 min of infusion period. The second, the 
infusion period (60 min) was divided into two parts, the first part (0-30 min), PRO or REM 
was administrated independently (sole), and then followed by their co-administration in the 
next part (30-60 min). The concentrations of PRO and REM in rat plasma were calculated 
from the corresponding calibration curves equation. The plasma concentration-time profile of 
PRO (plasma concentrations, µg/mL) and REM (plasma concentrations, ng/mL) were 
constructed for each individual subject after sole and after co-administration. A mathematical 
trapezoid method was used for area under the curve (AUC) calculations. In the experiments of 
sole administration and sole/co-administration, the AUCs were calculated in two separated 
periods, from 15 to 30 min and from 45 to 60 min. The AUC in the part of sole administration 
(from 15 to 30 min) and AUC in the part of co-administration (from 45 to 60 min) were 
compared, and also in the part of sole administration from 15-30 against the part 45-60 min. 
The significance difference between the A UC through the two periods were confirmed using 
paired Student's t-test at the statistical significance set at P < 0.05. 
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2.3. RESULTS AND DISCUSSION 
2.3.1. Optimization of the Assay Conditions 
The monolithic column in the present study was effectively used for the present LC-
MS/MS method with a short time of separation, a high mechanical stability, long operative 
lifetimes and much lower back pressure. 
For selective analysis in the present method, the composition of the mobile phase was 
examined. The combination of acetonitrile and 10 mM ammonium acetate buffer was useful 
for separation PRO, REM and the IS. Additionally, the effect of ammonium acetate buffer pH 
and acetonitrile content in the mobile phase on the peak area of the analytes were examined 
and optimized. The maximum and constant peak area of PRO was given by more than 3.5 of 
pH, whereas the maximum peak area of REM at pH 3.5 was observed as in Figure 11. 
Therefore pH 3.5 was selected in the following experiment. Next, acetonitrile content ranging 
from 55 to 90% in mobile phase was examined. Increasing of the peak area of both analytes 
with increasing of acetonitrile content in mobile phase was observed, Figure 12. A 90% of 
acetonitrile content was selected in the following experiment. 
Preliminary studies for selection of ISs were performed. CLO, FLU, 2,6-di-tert-butyl-
4-methylphenol and finally CBZ, were examined. Among them, CBZ was eluted with similar 
retention time of the analytes and its extraction recovery from plasma was comparable to PRO 
and REM. 
The present method used easily negative- and positive-ionization changeable LC-
MS/MS, as PRO could be determined by ESI- mode, whereas REM and IS were determined 
by ESI+ mode. In a full scan spectra, the predominant molecular ions [M-H]" or [M+Hr with 
an mlz 176.94, 377.04 and 237.07 for PRO, REM and IS, respectively were formed. The most 
abundant ions (of the product-ions) mass spectrums were formed at m/z 160.87, 317.04, and 
194.02 for PRO, REM, and IS, respectively. 
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However the sensitive transition of mlz 237.07-194.02 for IS, was less selective, 
with regard to the endogenous plasma matrix. Therefore, the SRM transitions of m/z 
176.94-160.87 for PRO, m/z 377.04-317.04 for REM and m/z 237.07-220.01 for IS were 
selected during the study. 
The corresponding full-scan ESI--MS/MS and ESJ+-MS/MS spectra for the target 
analytes are shown in Figure 13. The capillary and cone voltages and collision energies were 
studied and optimized to obtain the greatest intense of the most abundant product ions for 
further MS/MS experiments, as in Figure 14A-C and as in Table 4. 
It was found that the source temperature and the desolvation temperature did not 
significantly influence the MS behaviour of these analytes and remained unchanged at the 
recommended value of 120°C and 350°C, respectively. 
Other MS conditions, including Desolvation/Cone gas flow, RF lens voltage, and 
Extractor voltage, were maintained at the auto-tuned (default) values, since they did not 
significantly affect the collision behaviour of the analytes. The analyzer parameters were kept 
in recommended SIM mode, and the Entrance/Exit were modulated to -1 and + 1, respectively. 
At the first the ion suppression for the analytes, due to the plasma matrix, was 
prohibited by adding a volume acetonitrile for deproteinization. Therefore the certain 
acetonitrile volumes (ranging from 40 to 100 µL) were examined; the maximum peak area 
with I 00 µL acetonitrile could be cleared from ME. Next; in order to select the proper organic 
extractor for LLE procedure; different organic solvents such as hexane, ethylacetate, and t-
BME were examined. As the results t-BME gave the acceptable recoveries of all the analytes; 
86.0±7.0% and 95.0±6.0% for PRO (0.5 and 10 µg/mL); 79.0±12.0% and 86.0±9.0% for REM 
(1 and 50 ng/mL) and 80.0±5.0% for IS (1 µg/mL). 
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Figure J J. Effect of pH of 10 mM ammonium acetate buffer in the mobile phase on the peak area of 
PRO and REM. Sample: standard, 0.5 µg/mL for PRO and 5 ng/mL for REM. 
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Figure 13. Mass spectral of[M-H]- ion of PRO using ESJ- and [M+Ht of REM and IS using ESI+. 
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Figure 14. Optimized conditions for capillary (A), cone voltages (B), and collision energy (C). 
Sample: standard, I µg/mL for PRO and 5 ng/mL for REM and 1 µg/mL for IS. 
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2.3.2. Method Validation 
2.3.2.1. Selectivity 
The selectivity of the proposed method for any interference in the retention time of the 
analytes was estimated by analyzing ten of different blank rat plasma. Figure 15 is the 
representative chromatograms of drug free rat plasma and that spiked with 500 ng/mL of PRO, 
5 ng/mL of REM and 1 µg/mL of IS. Moreover, the typical chromatograms of plasma after 10 
min of PRO and REM co-administration are illustrated in Figure 16. The retention time of IS, 
PRO and REM was 3.19, 3.63 and 7.01 min, respectively. 
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Figure 15. Representative SRM chromatograms of drug free rat plasma (A) and that spiked with PRO, 
REM and IS (B). Sample: spiked, 500 ng/mL for PRO, 5 ng/mL for REM and 1 µg/mL for IS (20 µL 
of stock solution, 11.1 µg/mL in acetonitrile ). 
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Figure 16. Representative SRM chromatograms of plasma sample before administration of drugs (A) 
and after I 0 min from PRO and REM co-administration (B). 
2.3.2.2. Matrix Effect, ME 
The LC-MS(/MS) is the instrument of choice used for quantitative bioanalysis due to 
its inherent sensitivity and selectivity. However, it is not free from drawbacks such as the ME 
phenomenon, that the co-eluting compounds may suppress or enhance the ionization of the 
analytes of the interest. The ME considerably affects the limit of LOD, LOQ, linearity, 
accuracy and precision of the developed LC-MS(/MS)179• 181 • 182l. Numerous factors as 
endogenous phospholipids, dosing media, formulation agents and mobile phase modifiers 
and/ or the biological samples pre-treatment and clean up procedure can causes the ME 183-185l. 
Therefore, an assessment of the ME and a minimization of ME are critical for the reliable 
evaluation of newly developed LC-MS/MS methods 186l. By the way, the current FDA 
guidance documents requires the study of ME as a part of the developed LC-MS(/MS) 
validation 154l. 
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MF of one signifies no ME, a value of less than one suggests the suppression of 
ionization and a value that is greater than one signifies ionization enhancement 179, 187l. An 
absolute IS-MF of one is not required for a reliable analytical assay. However, the variability 
(RSD%) in MFs should be less than or equal to 15% to ensure the reproducibility of the LC-
MS/MS analysis 179l. 
The result of IS-MF at low concentrations of PRO and REM in plasma shows that, a 
slightly ME is present as indicated by values of> 100% (peak area ratio was 1.08±0.12 for 
PRO (0.5 µg/mL) and 1.14±0.17 for REM (1 ng/mL)) in the spiked plasma samples post-
extraction. Also the ionization enhancement for PRO and REM at their high concentrations 
was similar and kept consistent (peak area ratio was 1.1±0.1 for PRO (10 µg/mL) and 1.2±0.1 
for REM (50 ng/mL)). Moreover, the variability (RSD%) in the present method was 11.3% 
and 8.2% for PRO (at 0.5 µg/mL and 10 µg/mL) and 15.0% and 11.5% for REM (at 1 ng/mL 
and 50 ng/mL) respectively, which indicates that the samples analysis were reproducible. 
Therefore, and despite a slight IS-ME was observed, the present method was considered 
reliable and reproducible for PRO and REM determination. 
2.3.2.3. Linearity, LODs and lower LOQs 
Calibration curves were constructed in rat plasma in the concentration ranges of 0.27-
10 µg/mL for PRO and 0.17-50 ng/mL for REM. The analyte on IS peak area ratios were 
found to have a good linearity with the selected concentration range for all the analytes (r 2: 
0.976). The calibration curves' equations for PRO and REM respectively were; y = 0.02x + 
0.01 and y = 0.76x + 0.38. The LODs for PRO and REM were 0.16 µg/mL and 0.10 ng/mL, 
whereas the lower LOQs were 0.27 µg/mL for PRO and 0.17 ng/mL for REM. 
The difference in the sensitivity of the analytes was observed due to using different 
ion detection mode and the selected conditions were directed toward the most potent analyte 
(REM) which used in low plasma concentrations during the clinical practice 58, 188l 
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However, the obtained sensitivity for PRO was sufficient for its determination in the 
plasma samples during this study; as the difference in clinically used concentrations between 
PRO and REM is 1: 1000 times. 
In a comparison with the other reported methods (used LC-MS/MS) for analysis of REM 
individually, the sensitivity of the present method was comparable with the reported on 116>. 
Moreover, the proposed method was more rapid than some of reported methods that are for 
determination of PRO 111> or REM 111• 122> in plasma. 
2.3.2.4. Accuracy and Precision 
The accuracy of the proposed method was estimated by comparing the measured 
concentrations of PRO and REM spiked in plasma with the theoretical (calculated) 
concentration values of the standard. The calculated accuracy (as a relative error (RE) ± SD) 
for PRO or REM was found between -19.4±5.6% or -0.0±5.4% indicating an acceptable 
accuracy for the proposed method. The intra- and inter-day precisions were expressed in terms 
of RSDo/o between the peak area values. The results showed that the intra- and inter-day 
variation at three different concentrations levels of PRO and REM were within the acceptable 
validated range as the RSDo/o was found less than 15% for intra- and inter-day precision as 
shown in Table 5. 
Table 5. Accll:facy and pre:ision of the woposed LC-MS/MS method. . ..... • ...•. 
Spiked tone., ·'f\~ciiti~y% Ptecisie>n,RSD% (n=5) 
ng/mL (RE1±S.Q! n=S) Analyte . Intra-day ln!er-day 
500 -19.4±5.6 6.4 10.2 
PRO 2000 -0.0±5.4 1.3 11.4 
10000 -7.0±2.8 3.2 8.2 
-0.3±5.1 5.0 11.9 
REM 10 -1.9±8.4 3.7 12.7 
50 -6.2±2.1 2.3 9.8 
1RE =Relative error (overall mean assayed concentration - added concentration)/added concentration x 100. 
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2.3.2.5. Administration study of PRO and REM 
The proposed method was applied to estimate drug-drug interaction after co-
administration of PRO and REM to rats. The dose of PRO and REM for both sole and co-
administration were 125 µg/kg/min and 125 ng/kg/min, respectively. Accordingly, these doses 
were included in the therapeutic range for human usage to PRO and REM co-administration 
188• 189l. The plasma concentration-time profiles of both analytes for sole and sole/co-
administration were constructed as shown in Figure 17 and Figure 18. 
After 10 min of administration the concentration of both drugs could be confirmed to be 
stable. The AUC1s-Jomin and AUC45-60min (sole administrations) were 7.19±0.58, 7.95±1.08 
µg/mL.min for PRO; 4.42±0.11, 4.91±0.19 ng/mL.min for REM, Figure 17. The AUC1s-Jomin 
and AUC45-60min (sole and next co-administration) were 8.40±1.22, 8.70±1.42 µg/mL.min for 
PRO; 5.49±0.99, 8.76±0.94 ng/mL.min for REM, Figure 18. 
0 15 30 45 60 
Time after administration, min 
Figure 17. Plasma concentration-time profiles after sole administration of PRO and REM. 
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Figure 18. Plasma concentration-time profiles after sole and co-administration of PRO and/or REM. 
The plasma concentrations of PRO and REM seem to be constant after sole 
administration experiments (from 0-60 min), also PRO concentration was stable in sole as in 
co-administration experiments (P = 0.44). While a significant increasing in REM 
concentration after co-administartion (from 30-60 min) was observed (P = 0.01). 
As the studies before for drug-drug interactions between PRO and REM or REM-
analogue (fentanyl or alfentanil) 58• 190) showed that the PRO-opioid interactions. Even though 
ADME of REM is not the same, but the same PK alterations were obtained in the presence of 
co-administrated PRO. As in the two mentioned studies, the suggested mechanisms for this 
alteration was the hemodynamic changes which caused by PRO, we also supposed that the 
same cause is exist in our present study between PRO and REM. Therefore, the further studies 
to interpret the particular mechanism of this action are necessary. 
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2.4. CONCLUSION 
The first and rapid LC-MS/MS method developed and validated for simultaneous 
determination of PRO and REM in rat plasma. The results of the validation study showed the 
developed method was selective, accurate, and precise to meet the requirements for 
determination of PRO and REM concomitantly administered. The proposed method could be 
successfully applied to study the PK interaction of PRO and REM in rat plasma. Moreover, 
the method is considered from the rare methods applied LC-MS/MS method determination for 
acidic (PRO) and basic (REM) analytes using an IS in rats plasma. Therefore we are 
convinced that our contribution is valuable as a scientific work. 
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CHAPTER3 
DEVELOPMENT AND VALIDATION OF LIQUID 
CHROMATOGRAPHY-TENDEM MASS SPECTROMETRY FOR 
STUDY OF THE INFLUENCE OF CO-ADMINISTRATED 
ANTIEPILEPTIC DRUGS ON PLASMA CONCENTRATION OF 
PROPOFOL DURING ANESTHESIA TO RATS 
3.1. BACKGROUND 
Patients with epilepsy often require anesthesia for elective and emergency surgery. 
Therefore, an appropriate perioperative management of AEDs is vital in maintaining seizure 
control in these patients 62l. PRO and CBZ are known individually, to inhibit or induce a 
variety of hepatic cytochrome enzymes. Up to date, there is no data described whether and 
what degree CBZ affects the plasma concentration of PRO. Therefore, in the present study a 
rapid, sensitive, and selective LC-MS/MS method was developed and validated for 
simultaneous determination of PRO and CBZ. MDZ was used as an IS and as well as a 
valuable probe to predict the unwanted therapeutic outcomes such as lack of therapeutic 
efficacy or potentially harmful response during the study development. The proposed method 
had the opportunity to assess the PK interactions analysis between PRO and MDZ or PRO 
and CBZ in rat plasma. 
3.2. MATERIAL AND METHODS 
3.2.1. Reagents and Standards 
MDZ was obtained from Wako Pure Chemicals, Ltd. (Osaka, Japan) and all other 
reagents were of analytical reagent grade; as in Chapter 1 and Chapter 2. 
3.2.2. Standard Solutions and QC Samples 
The stock solutions of PRO, MDZ, and CBZ at the concentration of lmg/mL were 
prepared by dissolved an appropriate amount of each drug in acetonitrile and stored at 4°C. 
The working solutions were prepared by dilution of the stock solutions serially in acetonitrile 
to obtain the spiked plasma concentrations over the range of 0.05-100 ng/mL for PRO, 2-100 
ng/mL for MDZ and 7-1000 ng/mL for CBZ. 
70 
The analytical standard and QC samples were prepared by spiking blank rat plasma 
with standard working solution (20 µL) during validation and each experiment run in the PK 
study. The QC samples were prepared at concentrations 1, 50 and 100 ng/mL for PRO; 2, 50 
and 100 ng/mL for MDZ; and 7, 100 and 1000 ng/mL for CBZ. For administration study; the 
solutions of PRO (5 mg/mL), MDZ (2 mg/mL) and CBZ (5 mg/mL) were prepared in 
Intralipid® 10% emulsion. 
3.2.3. LC-MS/MS System and Conditions 
A Waters 2695 separation module (as described in Chapter 2) was used for solvent 
and sample delivery. The chromatographic separations were achieved by using a Chromolith 
Performance RP-18e at 30°C of column temperature. The mobile phase was a mixture of 
acetonitrile-ammonium acetate buffer (10 mM, pH 4) (=90:10%, v/v), pumped at a flow rate 
of 0.5 mL/min. An ESr- and ESr+ easily changeable Quattro micro™ triple quadrupole mass 
spectrometer (as described in Chapter 2) was used for mass analysis and detection. Mass 
spectrometric analysis was performed in a negative-ion mode for PRO and a positive-ion 
mode for MDZ and CBZ. Nitrogen gas was used as desolvation (500 L/h) and nebulizer (50 
L/h) gas. The source and desolvation temperatures were kept at 120°C and 350°C, respectively. 
The selected ESI-MS/MS parameters are listed in Table 6. The LC-MS/MS system was 
controlled by MassLynx™ V 4.0 software (Waters Co.). 
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Table 6. Selected ion transitions (m/z values) and mass spectrometric parameters for analysis of PRO, 
MDZ, and CBZ in SRM mode. 
EI?anune 
Precursorion,m/z 176.94 [M-H]- 326.74 [M+H]+ 237.07 [M+Hj+ 
Product ion, mlz 176.94 291.90 194.02 
Ionization ESJ- ESI+ ESJ+ 
Detection mode SRM SRM SRM 
ESI Capillary voltage, kV -3.0 +3.0 +3.0 
Cone voltage, V -35 +40 +25 
Collision energy, eV 8 25 20 
Ion energy l, V 
Ion energy 2, V 2 2 
Source temperature °C 120 120 120 
Desolvation temperature, °C 350 350 350 
3.2.4. Plasma Pre-treatment 
An aliquot of 200 µL of rat plasma spiked with 20 µL of MDZ or CBZ (spiked 
solutions concentration, 50 ng/mL of MDZ or CBZ as the ISs) was loaded to an Agilent® 
Bond Elut-Cl8 cartridge (100 mg, I mL), pre-conditioned with methanol then water (I mL). 
The washing step was 500 µL of 10% methanol (twice) and the elution was performed with 
400 µL of methanol then 20 µL of the eluent solution was inject directly to the LC-MS/MS for 
analysis. 
3.2.5. Method Validation 
The validation parameters, such as selectivity, ME and reproducibility, calibration 
curves linearity, LODs, LOQs, accuracy, precision, extraction recoveries and stability study 
were estimated according to the FDA guideline for validation of the bioanalytical methods 154>. 
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Blank rat plasma samples obtained from different rats were tested for any visible 
interference at the retention time of the analytes. In order to evaluate the absolute ME on the 
ionization of the analytes, blank rat plasma samples obtained from ten different rats were 
extracted and spiked at QC samples (low, middle, and high concentration levels of the 
analytes). These samples were injected together with samples containing no matrix 
components (pure standard in the elution solvent, 90% methanol) then the ME was calculated 
as IS-MF. 
The two calibration curves for PRO (using 20 µL spiked volumes of ISs; CBZ or 
MDZ, 50 ng/mL for each) were assessed by five concentration points (1, 5, 10, 50 and 100 
ng/mL); the calibration curve for MDZ (20 µL spiked volume of CBZ (IS, 50 ng/mL)) was 
assessed by five points (2, 8, 25, 50 and 100 ng/mL) and finally the calibration curve for CBZ 
(20 µL spiked volume of MDZ (IS, 50 ng/mL)) was assessed by five points (7, 25, 100, 500 
and 1000 ng/mL). The LODs and LOQ were defined as the analyte's concentration that giving 
peak area at SIN of 3 and 10, respectively. Peak area ratios of the analytes to IS were plotted 
against analytes concentration. The standard curves were assessed by equations for linear 
regression with a weighting factor of reciprocal of concentration (1/x) in the concentration 
ranges as mentioned above. The analytes peaks should be identifiable, discrete, and 
reproducible with precision of 20% and accuracy of 80-120%. The accuracy and precision of 
the proposed method were assessed by determining the QC plasma samples spiked at three 
concentration levels (five samples for each concentration) on five different validation days. 
The accuracy was expressed as a percentage of the calculated concentration divided on the 
nominal (theoretical) concentration. The intra- and inter-day precisions were determined as the 
RSDo/o. The criteria used to assess the suitability of accuracy and precision was as follows: the 
accuracy was within 15% of the nominal value except at the LOQs, where it should not 
deviate by more than 20% and for the precision, the RSDso/o did not exceed 15% except for 
the LOQs, 20% 154l. 
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The extraction recoveries of the analytes were determined by comparing the peak 
areas of extracted analytes spiked at three concentration levels, for all the analytes with that of 
the non-extracted pure standards (at the same concentration levels (n = 5)). 
The stability of analytes was assessed by determine QC samples at low, middle and 
high concentration levels with five measurements for each concentration, exposed to different 
time and temperature conditions. The stability study involved the stability after three freeze-
thaw cycles; stability at room temperature (25°C) for 4 h and finally, the stability of the 
extracted sample for 12 h. The concentrations of the analytes for each time point in the 
experiments were compared to a triplicate set of freshly prepared samples in the same 
concentrations. In all stability experiments, analytes were assumed stable when the deviation 
of the mean concentrations of the test samples from the controls was within ± 20%. 
3.2.6. Administration Design and Sampling Time Schedule 
The administration study was performed using male Wistar rats (as described in 
Chapter 1 and Chapter 2). PRO in Intralipid® emulsion (0.125 µg/kg/min) was 
administrated to the rats by i. v. infusion route for 60 min; MDZ and CBZ in Intralipid® 
emulsion (2 and 5 mg/kg, i.p.) were administrated to the rats with the injection volume given 
as I mL/kg of rat body weight. Following dosing administration of PRO, MDZ, and CBZ, a 
volume of:::: 0.350 mL blood sample was withdrawn from femoral artery of the rat at 5, 10, 15, 
20, 25, 35, 45, 55, 65, 90, 120, 180, and 240 min as shown in Figure 19. Meanwhile a volume 
of 0.350 mL of saline was given to the rat after each sampling for keeping body balance. 
Each of the collected blood samples was added to eppendorf tubes contained 
EDT A.2Na powder for plasma preparation. The plasma samples were prepared directly by 
centrifugation (2000g) for I 0 min at 4°C then stored at -30°C until analysis. 
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Cannula insertion in femoral 
vein for i. v. infusion I PROlinfusion.l + MDZ or CBZ, i.p. i ~ t 
t··. Stabilization for 60 min 90 120 
Cannula insertion in femoral f 5 lO-ls-2o-25-35-45-55-65i 
artery for blood samples ~-------------------------J 
180 
Time after administration, min 
Figure 19. Sampling schedule for rat plasma administrated with PRO (and/or) MDZ, CBZ. 
3.2.7. PK Calculations 
240 
The concentrations of PRO, MDZ and CBZ in rat plasma were calculated from the 
corresponding calibration curves equation. The plasma concentration-time profiles of PRO, 
MDZ and CBZ (plasma concentrations, ng/mL) were constructed for each individual subject 
after sole and after co-administration. In case of PRO, a mathematical trapezoid method was 
used for AUC calculations. In the experiments of sole administration and co-administration, 
the AUCs were calculated from 10 to 240 min. Then the AUCs for sole administration and for 
co-administration were compared. 
For MDZ and CBZ, the peak plasma concentration (Cmax) and the time to reach the 
peak plasma concentration (Tmax) were calculated form the actual plasma level data. The rate 
constant for plasma drug elimination (i.e. Ket) was calculated by the regression analysis of the 
monoexponential decline line of the Jog of plasma drug concentration versus time curve. The 
elimination half-life (T112) was calculated using formula T1 12 = 0.693/kei. The Cl was calculated 
as the dose/A UC for concentration versus time (A UC0-240). Other parameters such as A UCo-240, 
and the mean residence time (MRTo-240) were calculated by implicating moment analysis 
model 191 l. All the data are presented as the mean± standard deviation (SD, n=3). Statistical 
analysis was assessed by un-paired Student's t-test with p < 0.05 being considered significant. 
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3.3. RESULTS AND DISCUSSION 
3.3.1. Optimization of the Assay Conditions 
In this study, modifications were performed to improve the pervious method (Chapter 
2) selectivity and sensitivity for PRO and CBZ. Moreover the modified method was extended 
to separate MDZ simultaneously with PRO and CBZ. 
The effect of ammonium acetate buffer pH in mobile phase on the peak area of the 
analytes was examined. The maximum and constant peak area of PRO was given by more than 
4 of pH, whereas the maximum peak area of CBZ and MDZ at pH 4 was observed as in Figure 
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pH of 10 mM ammonium acetate buffer 
Figure 20. Effect of pH of 10 mM ammonium acetate buffer in the mobile phase on the peak area of 
PRO, MDZ and CBZ. Sample: standard, 2 ng/mL for PRO, and 10 ng/mL for MDZ and CBZ. 
A 90% content of acetonitrile content in mobile phase gave the maximum peak area 
for all the analytes (as the previous study in Chapter 2). In the present study MDZ was used 
as an IS for co-administration study between PRO and CBZ; whereas CBZ was used as an IS 
for co-administartion study between PRO and MDZ. The method used an easily changeable 
negative- and positive-ionization LC-MS/MS spectrometry, as PRO could be determined by 
ESI- mode, whereas MDZ and CBZ were determined by ESI+ mode. 
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In a full scan spectra, the predominant molecular ions [M-H]" or [M+Ht with an mlz 
176.94, 237.07 and 326.74 for PRO, CBZ and MDZ were formed. The most abundant ion of 
the product-ions mass spectra were formed at mlz 176.94, 194.02, and 291.90 for PRO, CBZ, 
and MDZ. In the present study the false mlz transition 176.94---+ 176.94 for PRO determination 
in SRM was used because of the small intensity ratio of product/parent ions at the true 
transition 176.94---+ 160.87. The complete separation of all analytes within 5 min was achieved 
without interfering peaks from plasma samples at the analytes retention time. The 
corresponding full-scan ESI--MS/MS and ESi+-MS/MS spectra for PRO, MDZ and CBZ are 
shown in Figure 13 (Chapter 2) and in Figure 21 in this Chapter. 
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Figure 21. Mass spectral of [M+Ht ofMDZ using ESI+. 
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The capillary and cone voltages and collision energies were studied and optimized to 
obtain the greatest intense of the most abundant product ions for further MS/MS experiments, 
as in Figure 22A-C and Table 6. It was found that the source temperature and the desolvation 
temperature did not significantly influence the MS behaviour of these analytes and remained 
unchanged at the recommended value of 120°C and 350°C, respectively. 
Other MS conditions, including Desolvation/Cone gas flow, RF lens voltage, and 
Extractor voltage were maintained at the auto-tuned (default) values, since they did not 
significantly affect the collision behaviour of the analytes. The analyzer parameters were kept 
in recommended SIM mode, and the Entrance/Exit were modulated to -1 and +l, respectively. 
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Figure 22. Optimized conditions for capillary (A), cone voltages (B), and collision energy (C). 
Sample: standard, 2 ng/mL for PRO, and 10 ng/mL for MDZ, and CBZ. 
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SPE is designed for rapid, selective sample preparation prior to chromatographic 
analysis. it is a form of digital (step-wise) chromatography designed to extract, partition, 
and/or adsorb one or more analytes from a liquid phase (the biological sample) onto the 
stationary phase (sorbent or resin). Therefore, the cartridge is designed for a single use in 
order to eliminate the possible carry-over problems. 
In the present study, a simple, rapid, and selective clean-up procedure based on SPE 
for plasma extraction process was carried out. The washing and elution solvents 
(methanol/water mixture) were studied and optimized (Figure 23A and B) for the effective 
eliminate of plasma matrix components, without any further pre-treatment. 
From the literatures, PRO is highly (98%) bounds with albumin and red blood cells 
after i. v. injection. MDZ and CBZ also are highly (96% and 70%) bound with albumin and a-
acid glycoprotein. The remainder of PRO, MDZ or CBZ exists in blood as a free type 28• 79• 85l. 
Protein-bound drugs are not detected by the present method only we detected the free type. 
The recoveries of PRO, MDZ, and CBZ from rat plasma following SPE extraction 
were ranged from 82.9±4.8 to 107 .0± 7 .1 and were similar at all analyte concentrations without 
significant concentration dependence. The reproducibility and recoveries of SPE were 
determined from five repetitions at three concentration levels for all the analytes, the 
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Figure 23. Effect of methanol/water ratio(%, v/v) in washing (A), or elution (B), steps on the analyte 
recoveries using Bond Elut-C 18 cartridge. Sample: spiked concentration, 2 ng/mL for PRO and 10 
ng/mL for MDZ and CBZ. 
Table 7. The recoveries for PRO, MDZ and CBZ after extraction from rat plasma by SPE (n=5). 
PRO (CBZ IS) 10 
100 






















aThe recovery: was determined by comparing the area of the extracted analytes with that of the pure 
standards. 
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3.3.2. Method Validation 
3.3.2.1. Selectivity 
The LC-MS/MS method demonstrated high specificity because only ions derived from 
the analytes of interest were monitored. The selectivity of the proposed method towards 
endogenous plasma samples was estimated by analyzing ten of different blank and spiked rat 
plasma at LOQ levels. Endogenous peak at the retention time of the analytes were not 
observed for any plasma samples evaluated. 
Representative chromatograms of blank rat plasma and that spiked with PRO (at 1 
ng/mL); MDZ and CBZ at LOQ (2 and 7 ng/mL, respectively) are shown in Figure 23A and B. 
Moreover, the typical chromatograms of plasma after 10 min of PRO and MDZ (using CBZ, 
50 ng/mL as an IS); or PRO and CBZ co-administration (using MDZ, 50 ng/mL as an IS) are 
illustrated in Figure 24A and B. 
The retention time of CBZ, PRO, and MDZ was 3.26, 3.79, and 3.95 min, respectively. 
Therefore the method had a significantly shorter total running time (;:::5 min) as the first 
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Figure 24. Representative SRM chromatograms of drug free rat plasma (A) and that spiked with 
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Figure 25. Representative SRM chromatograms of 10 min after co-administration of PRO and MDZ 
(A); PRO and CBZ (B). 
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3.3.2.2. ME 
The IS-MF as calculated for the present work showed no significant ion suppression 
or enhancement at low, middle, and high concentrations of PRO, MDZ, and CBZ. The RSD% 
was ranged from 1.9 to 11.9% for all the analytes (Table 8), which indicates that the samples 
analysis were reproducible. 
1.0±11.9 11.9 
PRO 10 1.1±6.3 6.0 
100 1.1±1.9 1.9 
2 0.9±8.7 9.4 
MDZ 50 0.9±5.3 5.8 
100 1.0±4.9 5.1 
7 1.0±4.8 4.9 
CBZ 100 1.0±4.7 4.8 
1000 1.1±7.3 6.9 
3.3.2.3. Linearity, LODs and LOQs 
Typical calibration curves for PRO, MDZ, and CBZ respectively were constructed in 
rat plasma in concentration ranges showed in Table 9. The analyte on IS peak area ratios were 
found to have a good linearity with the selected concentration ranges for all the analytes (r ~ 
0.991). The slopes, intercepts, and r values showed in Table 9. The lowest concentrations on 
the calibration curves for MDZ and CBZ were 2 and 7 ng/mL respectively. The analytes's 
responses at these concentration levels were> 10 times of the noise baselines of the drug free 
rat plasma. 
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The accuracy and precision at these concentration levels were acceptable, with the 
RSD% < 20% and the RE% < 15%. Thus, the lowest concentrations on the calibration curves 
were acceptable as LOQ for MDZ and CBZ. The LODs were calculated to be 0.6 and 2.1 
ng/mL respectively for MDZ and CBZ. For PRO the LOD was 0.02 ng/mL and LOQ was 0.05 
ng/mL. 
However, the obtained sensitivity for PRO, MDZ, and CBZ were sufficient for their 
determination in the rat plasma samples during this study with the doses that related to the 
clinical uses of human. 
Table 9. Linearity range, slope, intercept, and the correlation coefficient (r) for the calibration curves 
of PRO, MDZ, and CBZ. 
PRO (CBZ IS, 50 ng/mL) 1-100 2.90 1.10 0.998 
PRO (MDZ IS, 50 ng/mL) 1-100 1.20 2.20 0.991 
MDZ(CBZ IS) 2-100 0.05 0.04 0.991 
CBZ (MDZ IS) 7-1000 0.02 -0.06 0.994 
3.3.2.4. Accuracy and Precision 
The accuracy, intra- and inter-day precision data for PRO, MDZ, and CBZ are 
summarized in Table l 0. All the values of accuracy and precision were within the 
recommended limits 154l. The intra-day precisions ranged between 1.7% and 14.3%, and the 
inter-day precision was between 5.1 and 18.3; the mean errors were between -1.4±4.4 and 
9.8±11.0. 
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5 8.0±6.8 6.3 18.3 
PRO (CBZ IS) 10 1.0±9.0 8.9 8.9 
1000 -2.4±1.7 1.7 5.1 
5 7.0±7.5 7.1 17.6 
PRO (MDZ IS) 10 -1.6±10.1 10.2 14.0 
1000 -1.4±4.4 4.5 13.3 
2 9.8±11.0 9.9 17. l 
MDZ(CBZ IS) 50 3.6±12.0 12.4 15.3 
1000 2.8±5.0 4.9 10.0 
7 -15±8.7 10.2 13.0 
CBZ (MDZ IS) 100 -8.6±13.0 14.3 15.1 
1000 5.0 ±9.5 9.1 12.0 
3.3.2.5. Stability Study 
The stability of PRO, MDZ, and CBZ in rat plasma under different storage conditions 
is presented in Table 11. There was no significant degradation under these conditions 
described in this study, since their concentrations deviated by no more than 19.7% relative to 
the reference nominal concentrations. No degradation products were detected under the 
selected MS conditions. All the analytes can be safely analyzed after stored at room 
temperature for 4 h, at -30°C and after three freeze-thaw cycles. Also analysis of the QC 
samples following SPE extraction procedure showed no significant degradation after 12 h at 
room temperature. These results indicated the analytes were stable under routine laboratory 
conditions and no specific procedures (e.g., acidification or addition organic solvents) were 
needed to stabilize the analytes for daily clinical drug monitoring and PK studies. 
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Moreover, the proposed method might be used for routine monitoring of these drugs 
individually or simultaneously. 
-30°C freeze-thaw cycles 
0.8±5.0 -18.3 
PRO (CBZ IS) IO 9.6±4.3 -3.9 
IOO 83.6±5.1 -16.4 
0.9±9.5 -14.0 
PRO (MDZ IS) IO 9.0±4.1 -10.0 
IOO 99.7±4.9 -1.3 
2 1.8±6.6 -I0.2 
MDZ 50 41.0±6.1 -18.0 
100 80.5±1.9 -19.5 
7 6.4±5.8 -8.5 
CBZ 100 90.6±3.5 -18.9 
IOOO 852.0±8.3 -14.8 
4 hours at room temperature 
1 0.8±5.1 -19.4 
PRO (CBZ IS) 10 9.8±6.0 2.4 
100 86.0±5.IO -14.0 
1 0.9±7.4 -14.9 
PRO(MDZIS) IO 9.2±7.1 -8.6 
IOO I06.0±5.3 6.4 
2 1.9±8.3 -6.4 
MDZ 50 49.3±2.3 -1.4 
IOO 98.9±5.9 -1.1 
7 5.6±7.9 -19.7 
CBZ IOO 96.9±5 .2 -18.2 
IOOO 835.0±2.6 -16.5 
12 hours at room temperature (extracted samples) 
1 0.9±9.7 -14.8 
PRO (CBZ IS) IO I0.6±2.2 6.1 
IOO 84.0±1.2 -16.0 
1 0.8±3.2 -18.0 
PRO (MDZ IS) 10 10.1±2.5 0.8 
100 93.0±2.2 -7.0 
2 1.7±8.5 -15.6 
MDZ 50 41.7±4.0 -16.6 
IOO 80.0±2.1 -20.0 
7 5.9±1.8 -14.8 
CBZ 100 90.4±3.3 -11.6 
IOOO 823 .0±1.8 -17.7 
1RE=Relative error= (overall mean assayed cone. - added cone. /added cone.) x IOO. 
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3.3.2.6. Administration Studies of PRO and MDZ or PRO and CBZ 
Initially we evaluated the applicability of the proposed method to estimate drug-drug 
interaction after co-administration of PRO and MDZ. Teh et al. 192! were examined the effect 
of a continuous infusion (60 min) of PRO on the human plasma concentrations of MDZ; and 
according to their study there were no significant increases in the concentrations of MDZ 
administered concurrently with PRO; this may result from the lower plasma concentrations of 
PRO (1.5 µg/mL) in that study. In a next studies the plasma concentration of PRO was 
increased to be::::: 4 µg/mL, that resulted in the decrease of Cl of MDZ 87• 193>. Therefore, the 
PK interactions between PRO and MDZ are dose dependent. 
In the present study the interactions between PRO and MDZ was confirmed and used to 
predict that the efficiency of therapeutic dose of PRO which responsible on the CYP3A 
isoforms' activity inhibition. Also a lack of any clinically significant unwanted effects on 
coadministration of PRO with MDZ such as the respiratory depression would have resulted 
from the proper selected doses of PRO and MDZ (125 µg/kg/min, i. v. infusion and 2 mg/kg, 
i.p., respectively). 
After the interaction between PRO and MDZ was successfully studied, the method was 
used to evaluate the PK interactions between PRO and CBZ. PRO in rat plasma was 
monitored after sole and co-administration with CBZ. The dose of CBZ (5 mg/kg, i.p.) was 
effective dose as has been used previously for the study of PK of CBZ on rats 143) or on human 
to evaluate the CBZ interactions with other drugs 194• 195l . 
The plasma concentration-time profiles of PRO, MDZ, and CBZ after sole and co-
administrations were constructed as shown in Figure 26A-C. PRO sole or co-administration 
with MDZ and/or CBZ, was determined through 60 min of infusion time and then until 240 
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Figure 26. Plasma concentration-time profiles of: PRO after sole and co-administration with MDZ or 
CBZ (A); sole and co-administration with PRO ofMDZ or CBZ (Band C). 
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For PRO, after 10 min of administration, its concentration could be confirmed to be 
stable. TheAUC10-240min for sole administrations was 215.79±37.72 ng/mL.min. TheAUCs10-240 
after co-administration with MDZ and CBZ were 455.17±118.46 and 79.45±39.85 ng/mL.min, 
respectively. As the results revealed that the plasma concentrations of PRO were significantly 
increased after co-administration with MDZ (P = 0. 015) and decreased after co-
administration with CBZ (P = 0.013). 
For both MDZ and CBZ sole and co-administrations, Tmax, min was 25 min. The mean 
plasma concentrations, ng/mL were evaluated for the MDZ and CBZ after sole and co-
administration with PRO. The plasma concentration of both drugs was significantly (P = 0.009 
and 0.004 for MDZ and CBZ, respectively) increased after their co-administration with PRO 
compared to sole administration. The A UCo-240 was 4.90 x 103±0.20 after sole administration 
versus 6.28 x 103±0.23 ng/mL.min after co-administration for MDZ, and 21.54 x 103±6.98 
after sole administration versus 41. 70 x 103± 11.85 ng/mL.min after co-administration for CBZ. 
The T112, min (155.93±24.50 versus 283.58±58.44 for MDZ and 69.30±0.00 versus 
150.15±20.01 for CBZ); and finally the MRTo-240, min (95.79±2.04 versus 107.39±4.48 for 
MDZ and 71.36±3.92 versus 94.11±7.30 for CBZ) were significantly increased as the P values 
indicated in the Table 24 and 25. 
While the Ke1 was significantly decreased (at P = 0.012 for MDZ and 0.045 for CBZ) 
it was 0.005±0.001 versus 0.002±0.001 for MDZ; and was 0.011±0.004 versus 0.005±0.001 
for CBZ; and also the Cl, mL/min for MDZ was 404.58±17.21 versus 319.01±11.88 and for 
CBZ was 246.87±68.18 versus 127.31±39.41 were significantly decreased in the presence of 
PRO compared to sole administration at P = 0.010 and 0.042 for MDZ and CBZ, respectively. 
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Table 24. PK parameters of MDZ (2 mg/kg, i.p.) after its sole and co-administration with PRO (125 
µg/k mL, i. v. infusion for 60 min). 
Cmax, ng/mL 41.11±2.49 44.23± 1.3 0.150 
T1 12 , min 155.93±24.50 283.58±58.44 0.040 
AUCo-240, ng/mL.min 4.90 x l 03±0.20 6.28 x 103±0.23 0.009 
MRTo-240, min 95 .79±2.04 107.39±4.48 0.030 
Cl , mL/min 404.58± 17 .21 319.01 ± 11.88 0.010 
1Data are expressed as mean ± SD (n=3). 
2Un-paired Student's /-test: P < 0.05, significantly different from sole administrations. 
Table 25. PK parameters of CBZ (5 mg/kg, i.p.) after sole and co-administration with PRO (125 
i >/k >imL, i. v. infusion for 60 min). 
Cmax, ng/mL 309 .33±59 .53 422.68±91.47 0.079 
T112, min 69.30±0.00 150.15±20.01 0.001 
AUCo-240, ng/mL.min 21.54 x 103±6.98 41.70 x 103± 11.85 0.054 
MRTo-240, min 71.36±3.92 94.11±7.30 0.004 
Cl, mL/min 246.87±68.18 127.31±39.41 0.042 
The important role of the anesthetist is to minimize the risk of perioperative seizures, 
whilst providing adequate anesthesia to allow optimum surgical operating conditions. 
Moreover, the good knowledge with the PK interactions between the commonly used drugs in 
both anesthesia and epilepsy is essential. 
This study showed the concomitant administration of CBZ with PRO significantly 
decreases the plasma concentration of PRO. This indicated an enhancement of PRO 
metabolism leading to lower plasma concentration of PRO. Such a variation would lead to 
sub-therapeutic in case of PRO or super-therapeutic concentration in case of CBZ. 
Consequence lack of sedation effect of PRO and increase the toxic effects of CBZ. There is 
no other study investigating the interaction between PRO and CBZ during the anesthesia in 
human or animal 's application . The basis for studying the interaction between PRO and CBZ 
was the common metabolic pathway involving the isoenzymes CYP3A4. 
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In rats it has been seen that the isoenzymes CYP3A4 corresponding to CYP3A4 
activity in human hepatocytes 196l. Hence, any drug interaction occurring due to an effect on 
this particular CYP isoforms. In a previous study PRO doses required for sedation and times 
to the recovery of the eyelash reflex and spontaneous eye opening were evaluated, the 
required sedative dose of PRO for patients were received oral valproate treatment for 
moderate or severe mental retardation was significantly lower than the normal ones. 
Suggesting that valproate decreases the required sedative doses of PRO, and that the normal 
PRO dose may be excessive for patients receiving valproate treatment and induce 
complications or delay recovery from anesthesia 66l. Because valproate has been demonstrated 
to inhibit PRO metabolism in vitro 64• 65l. 
Inversely, in the present study the results revealed that, the co-administration of PRO 
and CBZ to rats, a significant (P = 0.013) decrease in the plasma concentration of PRO was 
detected when compared with the PRO sole administration. This finding is consistent with the 
literature as CBZ is an inducer (its unique difference than other AEDs) for several potential 
pathways of drug elimination, including CYPs isoenzymes such as CYPIA2, 2C9, and 3A4, 
as well as the active transporter P-glycoprotein 90l. 
According the present study, the required dose of PRO for the sedation of epileptic 
patients during the anesthesia should be increased in those receiving CBZ treatment to 
provide the adequate sedation. 
This is the first study to report the interaction between the antiepileptic CBZ with 
PRO. However, the importance of these findings should not be ignored. PRO is the most 
commonly hypnotics used in general anesthesia todays. CBZ is the most commonly used 
antiepileptic drugs and also indicated for trigeminal neuralgia, migraine headache and alcohol 
dependence, thus there is a significant percentage of population who required this drug in 
their life time 197l. 
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3.4. CONCLUSION 
In this study, the first and rapid LC-MS/MS for the simultaneous determination of 
PRO, MDZ, and CBZ in rat plasma was developed and validated. The sample pretreatment 
procedure was simple economic, rapid and selective for extraction of the analytes from the 
plasma. A detailed validation following FDA guideline indicated that the developed method 
had a highly sensitive, reliability, selectivity, and excellent efficiency with total running time 
of 5 minutes per sample, which is suitable for high-throughput PK studies. 
Moreover the proposed LC-MS/MS method was successfully applied to study the PK 
drug-drug interactions between PRO and MDZ or between PRO and CBZ in rats. The present 
study showed that CBZ can alter the plasma concentration of PRO to statistically significant 
level and also the presence of PRO affects the PK parameters of CBZ at significant level. 
However, further confirmation of these findings is required in the human studies using large 
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